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ON THE COVER: An image from a negative-space 3D printed model
of the ventricular and cisternal system in the brain obtained from
an MRI analysis and labeled with voice-activated LED lights. This
image was produced by Cullen Fleming, MSIV, while doing research
in neuroradiology under the guidance of research advisor Ramin
Javan, MD, associate professor of radiology.
Photos like Flemings, capturing the beauty and intricacy of
science, are featured annually in the George Washington University
(GW) School of Medicine and Health Sciences (SMHS) Art of Science
Contest. The competition began in 2018 as a means of highlighting
the research that SMHS medical students, graduate students, and
postdoctoral fellows are conducting.
Each year prizes are awarded for the top entries and the winning
images are displayed in Ross Hall, alongside those from previous
years.
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GW MEDICAL STUDENT RESEARCH
FOURTH-YEAR MEDICAL STUDENT DARA BAKER, BS ’16,
was awarded a fellowship as part of the National Institutes
of Health (NIH) Medical Research Scholars Program. The
year-long research immersion program fosters career
development among budding physician scientists. Baker is
using induced pluripotent stem cell technology to develop
retinal epithelial cells to treat degenerative eye diseases
under the mentorship of Kapil Bharti, PhD, senior investiga
tor at the National Eye Institute at the NIH.
In 2018, Baker received the William H. Beaumont Medi
cal Society Student Research Awards for her abstract, The
Role of DFMO in Helicobacter Pylori Infection: Modulation
of ROS Response. In 2015, she received the Luther Rice Un
dergraduate Research Fellowship through the GW Colum
bian College of Arts and Sciences.

METEOR Program

Robert Miller, PhD, GW vice president for research and
senior associate dean for research at SMHS, presented
Sarah McCormack, MSIV, with the 2019 Doris DeFord
Speck and George Speck Endowed Prize

Richard Simons, MD, senior associate dean for MD
programs and professor of medicine at SMHS,
presents the 2019 Walter Freeman Research Award for
best research paper to (from left) Tina Boortalary, MD
’19, (left) and Alastair Fritchen Murray, MD ’19, (right)
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The Mentored Experience to Expand Opportunities in
Research (METEOR) program is a competitive fellowship
for underrepresented-in-medicine students. Students
are supported for a six-week, pre-matriculation research
summer and enroll in the research track. Participants also
have the opportunity to work with a clinical and translational
researcher who will serve as a mentor during their time
in medical school, complete a second summer research
internship after Year 1, and conduct a research elective
during the third year of medical school.
https://tinyurl.com/y86oxwmb

GW Research Showcase, formerly GW Research Days, is a one-day event
highlighting the breadth of innovation and creativity across all disciplines at GW
This event invites students and trainees to present their work and compete for
top honors Participants have the option of showcasing their research through
interactive exhibits, in addition to poster presentations
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THE LAZARUS FAMILY SCHOLARSHIP PROGRAM
Christina Pugliese, MS IV,
and Sowmya Mangipudi
were the 2019 Lazarus Family
Scholarship recipients. The
program, established by
Gerald Lazarus, MD, class of
’63, and Audrey Jakubowski
Lazarus, PhD, supports medical students as they pursue
extraordinary educational
opportunities in health care.

The program provides pivotal experiences for future
leaders in health care, annually enabling one or more
students to pursue a project
or program. Students apply
in the spring of their second
year of medical school, and
scholarship winners receive
funding for their remaining
years of medical school.

r

RESEARCH SCHOLARLY CONCENTRATION

Each year, roughly 50 students elect to participate
in the Clinical and Translational
Research Scholarly
Concentration. The program
promotes mentored
research for students
during the summer
between MSI and MSII,
and enables them to attend
research lectures and followup with research scholarship.
For details, see smhs.gwu.edu/oso/
track-program/ clinical-and-translational-research
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Former Beaumont Society Co-Presidents, and current third-year medical Students,
Neil Almeida (far left) and Abby Pepin (far right) presented the annual William
Beaumont Research Award for the top medical student abstracts to 2019 winners
(from second left) Maria Cerezo, Neil Almeida, and Sharjeel Chaudry during
“Research Days at GW” 2019

REHEMA THOMAS is only in her
second-year MD student, but she
already has a head start on a spe
cialzation in radiation oncology.
During the summer of 2019, Thom
as participated in the prestigious
American Society for Radiation On
cology’s (ASTRO) Minority Summer
Fellowship.
“Radiation oncology is a feld
that’s lacking in diversity, and that is
something I want to make a change
in,” she said. “I want to make a dif
ference in these outcomes because
everyone deserves an equal chance
at survival and beating cancer.”
During her summer, Thomas
worked with ASTRO member Curti
land Deville, MD, clinical director of
radiation oncology at Johns Hop
kins Kimmel Cancer Center at Sibley
Memorial Hospital, on the use of
photon and proton therapies in soft
tissue sarcomas.
3

Letters:

Letter from the Presidents

Andrea Klein, MSII

Hira Mohyuddin, MSII
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As the co-presidents of the William
H. Beaumont Medical Research
Honors Society, we proudly present
the 2020 edition of Fusion, the ofcial medical research publication of
The George Washington University
(GW) School of Medicine and Health
Sciences (SMHS). Fusion is an entirely
student run publication that serves
as a platform for medical students to
share their work with the GW community. The fourteenth edition of
Fusion received a record number of
submissions spanning a broad range
of research areas, including basic science, clinical research, translational
research, biomedical engineering,
quality improvement, public health
and policy, education, and clinical
practice innovation.
This past year has been an exciting
time for the GW research community. The GW Strategic Initiative for
improving the Research Ecosystem
has set signifcant change in motion
with four main goals: increasing
support for faculty investigators,
enhancing GW’s research reputation
by promoting university-led discoveries, aligning the missions of the
research and academic enterprises,
and enriching the student research
experience by increasing access to faculty investigators. Additionally, the

current leadership of Beaumont has
spearheaded novel programs designed
to provide new medical students with
a structured path towards research
success during medical school. Our
most signifcant new program consists
of a lecture and workshop series on
navigating the research community,
obtaining funding, and organizing a
research project.
We wou ld like to tha n k our
mentors David Leitenberg MD,
PhD, director of immunology in the
Department of Laboratory Medicine
at Children's National Hospital and
associate professor of microbiology,
immunology, and tropical medicine
at SMHS; and Alison Hall, PhD,
associate dean for research workforce
development at SMHS, for their guidance as senior researchers and advisors for the Fusion journal. We are
grateful for the eforts of the executive
and editorial board members (listed
on the table of contents) and their
contributions to the journal.
We hope you enjoy this edition of
Fusion and that you consider contributing next year!

Andrea Klein MSII
Hira Mohyuddin, MSII
Co-Presidents of the William H Beaumont
Medical Research Honor Society
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Letter from the Editors
Scientific discovery and experimentation
advance patient care and shape the way physicians practice. With an array of scholarly
concentrations available to students at the
George Washington University (GW) School
of Medicine and Health Sciences (SMHS),
our classmates advance the feld of medicine
in every aspect, from improving health care in
low-resource regions to medical innovation and
policy writing, and everything in between. As
participants in these concentrations, medical
students are tasked with going beyond the
preclinical curriculum and addressing the
problems of today’s health care system. This
formative appreciation for scientifc discovery
is key to deepening our knowledge and changing
the way we — as the next generation of physicians — treat, cure, advocate for, and support
our patients.
According to the Association of American
Medical Colleges, the average pre-medical student matriculates with 1,251 hours of research.
GW SMHS students are able to continue developing these research skills at the professional
level in a variety of DC health care settings
including: GW SMHS, Children’s National
Hospital, Washington DC Veterans Affairs
Medical Center, and the National Institutes of
Health. Early research experiences allow our
students to be better prepared for careers in
academia and show substantial interest in their
chosen feld to support a strong residency application. Given the time constraints of medical
school, seeing a project through from conception
to publication is no easy feat, and one that should

be celebrated. Additionally, early involvement
enables the student to be involved in clinical
domains not previously explored and discover
their true interests. Finding one’s niche can be a
winding and roundabout process, where faculty
support can help a student not only develop
research skills, but clarity of career interest.
As junior Fusion journal editors, we are
delighted to highlight the diverse research
initiatives unique to GW SMHS and driven
by the strong intellectual curiosity present on
our campus. Along with the research opportunities at GW SMHS, Fusion provides yet
another opportunity for student involvement
in all aspects of the research process including
the art of presentation, manuscript writing,
and presentation. Participation in research is
benefcial for both the personal and professional
development of our medical students, but even
more so, for the better health for our society.
Health care is an ever-changing feld of practice
with advances in medicine, expanded evidence
sources, new treatment options, and changing
governmental regulations and models of care.
Early experiences in research equip our students
with the ability to navigate this complex terrain
and serve as leaders in the future.

Zachary Falk, MSI

Aneka Khilnani, MSI

Zoe Shancer, MSI

Zach Falk, MSI
Aneka Khilnani, MSI
Zoe Shancer , MSI
Muhammed el Shatanofy, MSI
Co-Directors of Fusion

Muhammed
el Shatanofy, MSI

LETTERS

5

Letters:

Faculty Advisor’s Perspective
As the faculty advisor for this year’s
issue of Fusion, it is an honor to contribute my thoughts about medical
education and research. As I’ve
become more involved with medical
student teaching over the last several
years, I am continually struck by the
diversity of student interests and
backgrounds that each class brings to
The George Washington University
School of Medicine. The students that
are admitted to the MD program at the
George Washington University School
of Medicine and Health Sciences
(SMHS) have already achieved a signifcant level of academic success, but
have also developed unique interests
that set them apart as individuals. It
is critical that, as students progress
through medical school and postgraduate training, there be opportunities to preserve and foster the
development of these existing and new
unique interests. “Fusion” is a superb
forum to celebrate some of the more
individualized talents and interests of
our students outside of the classroom.
Most students that enter medical
school have a curiosity and enthusiasm about how the complexities
of biological systems work and how
this relates to clinical care. And just
as importantly, many of our students
have a strong interest in the critical
role that public health systems play
locally, nationally, and globally in
impacting health. It is critical that this
enthusiasm be supported and allowed
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to grow, as it will inform and influence student career paths and impact
future attitudes toward patient care in
multiple and often unforeseen ways.
The students involved in research
and who have contributed to this issue
of Fusion have a special role. You serve
as role models to your peers by demonstrating a commitment to intellectual
curiosity as you progress through
medical school training.
Medical students at GW have multiple opportunities to pursue research
experiences and complete a scholarly
project outside of the required curriculum. Most commonly this involves
participating in one of the nine scholarly concentrations that provide an
academic structure and mentoring
help for students throughout the
four years of medical school. In
order to support these endeavors, students are also encouraged to compete
for external, nationally competitive
research fellowships, as well as our
own internal fellowship awards that
provide valuable fnancial support for
the students while they pursue summer
projects. Our students’ accomplishments are demonstrated by the many
poster presentations at GW Medical
Student Research day, presentations
at more specialized national and international meetings, and publications in
peer-reviewed journals.
As is evident in the following
pages, there are many ways to achieve
a meaningful research experience that

David Leitenberg MD, PhD, associate
professor of microbiology, immunology,
and tropical medicine at SMHS, and director
of immunology in the Department of
Laboratory Medicine at Children's National
Hospital

span a broad range of interests and
disciplines, including basic and translational science, clinical research, health
policy and public health research,
and education-related research. An
additional essential component of a
successful student research project is
the dedication and enthusiastic guidance provided by our faculty mentors,
both here at GW and at our DC area
partner institutions, as well as outside
academic centers nationally and internationally. We applaud and thank you
for your eforts.
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Basic Sciences / Infectious Disease:

Select gp120 V2 Domain Specifc Antibodies Derived from HIV
and SIV Infection and Vaccination Inhibit gp120 Binding to α4β7
Matthew Liu,
MSII
ADVISORS:
James Arthos, PhD,1
Anthony S Fauci,
MD1
National Institute
of Allergy and Infectious Diseases, National
Institutes of Health
1

The GI tract is preferentially targeted
during acute/early HIV-1 infection.
The basis for preferential targeting
of gut tissues is not well defined.
Recombinant proteins and synthetic
peptides derived from HIV and SIV
gp120 bind directly to integrin α4β7, a
gut-homing receptor.1
To cha racter ize the k i netic
gp120-α4β7 binding interaction, we
developed a novel surface-plasmon
resonance (SPR) based assay. In the
presence of a physiologic 1mM MnCl2
bufer, soluble α4β7 demonstrated comparable afnities for surfaces coated
with either MAdCA M-Ig fusion
protein or recombinant A244 gp120.
When MnCl 2 was removed, afnity
for both MAdCAM and gp120 fell
below the detection limit of this assay
(Figure 1). This observation suggests
that gp120 is likely to engage α4β7 only
on cells with an enhanced potential to
trafc to the gut. We replaced A244
gp120 with a synthetic cyclic 42 amino
acid peptide fragment (cV2) derived
from the V2 domain of 92TH023 gp120
(subtype A/E), whose sequence is
nearly identical to that of A244 gp120
V2. The afnity of this peptide (cV2
92TH023) for α4β7 was close to that of
A244 gp120, demonstrating that cV2 is
sufcient to mediate the high-afnity
interaction shown in Figure 1. When
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FIGURE 1: Specifc affnity of α4β7 for HIV gp120, MAdCAM and SIV gp120
A) Sensorgram of increasing concentrations (2-fold) of soluble α4β7 passed over
surface-immobilized MAdCAM in the presence of 1 mM MnCl2 for 120 sec, followed
by a 120 sec washout/dissociation phase Mass of bound α4β7 (y-axis) expressed
as response units (RU) Affnity expressed as KD (nM) is shown B) Same as in panel
A, with immobilized A244 gp120 C) Same as in panel A with immobilized MAdCAM
in the absence of divalent cations D) Same as in panel A with immobilized A244
gp120 in the absence of divalent cations E) Same as in panel A with immobilized cV2
92TH023 peptide F) Same as in panel A with immobilized 92TH023 cV2 peptide and
soluble α4β1 as the analyte Each sensorgram is representative of three independent
measurements of each analyte-ligand interaction
we replaced α4β7 with α4β1, affinity
for cV2 92TH023 was reduced by
>8000 -fold, demonstrating binding
specifcity and the fact that V2, like
M AdCA M, preferentia lly binds
to α4β7.
However, V2 peptides can adopt
either α helical or β strand structures.2
This is the case for a crystal structure of a linear V2 peptide derived
from HIV isolate 92TH023 gp120
that complexes with mAb CH58 in a
helical structure (Figure 2).3 CH58 is
a weakly-neutralizing mAb that was
generated from an uninfected immunized individual who participated in

the Rv144 vaccine trial.4 It recognizes
an epitope that maps within a short
region of V2 (AA 168–181) identifed
by sieve analysis as sites of vaccine elicited immune pressure in the RV144
trial (Figure 2). Other V2-specific
m Abs that recognize str uctures
in this same region include mAb
MK16C2 and mAb CAP228-16H,
which were generated from a HIVinfected subject and gp120 immunized rabbit, respectively. We evaluated the ability of each of these mAbs
to inhibit α4β7interactions with V2
Continued on p. 8
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Continued from p. 7
using a cell-based adhesion assay
where RPMI8866 cells expressing
α4β7 on the cell surface were allowed to
adhere to synthetic V2 cyclic peptides.
mAbs 2B4 and VRC01 were employed
as specifcity controls. mAbs CH58
and CAP228-16H, which recognize
a helical structure, inhibited α4β7
adhesion to V2 by >90% while mAb
830A, which shows preference for the
β strand, failed to show detectable
interference (Figure 2).
In this study, we characterized
the physical interaction between the
HIV envelope and α4β7, reasoning
that such information could provide
valuable insight regarding the role of
α4β7-expressing cells in HIV pathogenesis. We fnd that a subset of HIV
and SIV V2 antibodies derived from
both infected subjects and vaccine
recipients can efectively block V2 α4β7
interactions. Several of the vaccineelicited weakly neutralizing mAbs
have been linked with protection
from infection. Rather than binding
to the closed trimeric spike that is the
primary target of broadly neutralizing
antibodies, these mAbs recognize an
alternative conformation of the V2
region. This suggests that α4β7 also recognizes an alternative form of V2 that
is conserved in both HIV and SIV.

REFERENCES:
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FIGURE 2: The structures of V2 mAbs in complex with peptides, and V2 mAb
inhibition of α4β7 adhesion
A) Crystal structure of three V2 domain mAbs, CH58 (PDB ID: 4HPO), Mk16C2 (PDB ID:
6CEZ), and 830A (PDB ID: 4YWG) in complex with V2 peptides, and a superimposition
of CH58 and Mk16C2 binding to opposite sides of the same helical region of a V2
peptide Only the Fv regions are shown with the heavy chain, light chain, and the V2
epitope colored cyan, green, and magenta, respectively B) Amino acid sequence of the
V2 domain of 92TH023 Residues in contact with each mAb are highlighted in magenta
and the size of each amino acid is proportional to the contact surface area C) Adhesion
of RPMI8866 cells to cV2 92TH023 in the absence or presence of V2 mAbs: CH58,
CAP228-16H, 830A, and Mk16C2 Adhesion was determined at OD590nm and listed as
% inhibition in three or more independent experiments relative to cV2 92TH023 in the
absence of any inhibitor (y-axis) Error bars indicate SD
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Increased CD8+ T-cell Infltration of the Brain
Following Toxoplasma Gondii Exposure
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Schizophrenia is an idiopathic neuropsychiatric condition with heterogeneous clinical presentations.1 For this
reason, it is imperative to determine
novel therapeutic targets and biological pathways mediating the pathogenesis of this disorder. Schizophrenia
has been associated with chronic
Toxoplasma gondii infection in
numerous studies.1 Reactivation
of latent Toxoplasma gondii infection in animals results from antigen
specific CD8+ T-cell exhaustion
and is reported as a complication of
Toxoplasma gondii infection.2 The
objective of this study was to determine whether Toxoplasma gondii
(T. gondii) infection increases brain
T-cell infltrates as a potential trigger
for the pathogenesis and behavioral
alterations in schizophrenia. Namely,
whether there would be an increase in
the amount of T cells in brain tissue
following infection with T. gondii
and whether this difered from simple
disruption of the blood brain barrier
with lipopolysaccharide (LPS).
This study was conducted in a
translational research lab. A total
of 11 C57BL/6 mice were divided
into three groups. One group (n=2,
12 weeks old) was injected with LPS
22 hours prior to sacrifce and brain
collection. Successful blood brain
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FIGURE 1:
barrier disruption has been reported
between 18-24 hours following injection with LPS.3 The second group
(n=4, 7 weeks old) was orally infected
with ova transgenic parasites 5 weeks
prior to sacrifce and brain collection.
The control group (n=5, 8-12 weeks
old) was not infected with T. gondii
or injected with LPS prior to sacrifce
and brain collection. Brain tissue was
digested, stained with antibodies to
determine the amount of CD4+, CD8+,
CD3+/CD45+, and CD11b+ cells, and
prepared for Flow Cytometry. Flow
Cytometry results were analyzed with
FlowJo and GraphPad Prism software.
The data from this study was analyzed with GraphPad Prism software.
One-way ANOVAs were performed
to compare the percentage of CD4+,
CD8+, CD3+/CD45+, and CD11b+
cells from brain tissue bet ween
the diferent groups. The T. gondii
infected group exhibited the highest
average percentage of CD3+/CD45+
cells when compared to the LPS
(p<0.0001) and control (p<0.0001)

groups. The T. gondii group also
exhibited the highest percentage
of CD11b+ cells when compared
to the control (p<0.0001) and LPS
(p=0.0003) groups (Figure 1). Of the
CD3+/CD45+ cells, the percentage
of CD8+ and CD4+ was determined.
The T. gondii group exhibited the
highest percentage of CD8+ cells
when compared to controls (p=0.0377)
however there was no signifcant difference between the T. gondii and
LPS groups or the control group and
the LPS group. The control group
exhibited the highest percentage of
CD4+ cells when compared to the T.
gondii group (p=0.0080) and the LPS
group (p=0.0035) (Figure 2).
Compared to LPS and control
groups, T. gondii infected mice exhibited the highest percentage of CD3+/
CD45+ and CD11b+ cells. Additionally,
when compared to the control group,
the T. gondii group exhibited a higher
percentage of CD8+ cells, which
Continued on p. 10

9

Continued from p. 9
•

suggests that T. gondii infection
enhances CD8+ T-cell infltration and
may lead to enhanced T-cell exhaustion and the associated neurobiological and behavioral abnormalities
in schizophrenia. In the future, we
hope to further investigate whether
schizophrenia-like brain and behavioral changes occur in mice infected
with Toxoplasma gondii as a result of
PD-1 mediated CD8+ T-cell exhaustion. In addition, we hope to determine whether antibodies targeting
the PD-1 molecule will prevent these
changes.
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Type 1 diabetes (T1D) is an autoimmune disease characterized by pancreatic β-cell destruction, resulting
in insulin defciency. The pancreas is
anatomically unique because while it
is predominantly an exocrine gland,
1-2% of it is composed of endocrine
islets of Langerhans. Previous studies
have focused on the role of the endocrine pancreas on regulation of exocrine function. However, there is
evidence that the exocrine pancreas
also plays a role in regulating the
endocrine pancreas, yet the mechanism remains unclear.1 We previously showed that co-incubation of
murine islets in vitro with trypsinogen
induced β-cell proliferation. In this
study, we report the potential role of
another component of the exocrine
pancreatic secretome, trypsin inhibitor, on inducing pancreatic β-cells
into a proliferative phenotype in vitro.
Islets were isolated from C57BL/6
mice by a midline incision, cannulation of the common bile duct with
collagenase, and purifcation using a
Ficoll gradient centrifugation. Islets
were then plated in RPMI 1640/10%
FBS/ 1% penicillin streptomycin and
incubated at 37.5o C/ 5.0% CO2. After
overnight recovery, islets were placed
in media supplemented with 1/3 uL 1

[l
- g"'

°"'"'
s _Tubt-..00 1.tt-s: ~-n,. MctN AA,ne

§"•

~

FSC·A (x 1000)

262,l

University of Maryland School of Medicine

o.,~ont

1...:.

~edaAlont

1

001.fcs

10'

i
llr.4eCM~M0o!1"5

Tu~

001.~

enHte.-11

-□·
95 05%

~196
~13l

s 15%

l

+
Ill••

Live· 101

6

Pi~1flc 81ue-~

S Tube 001.fcs

262 1

Ki67'

2 06%

SUliR;,$7+-

I 03%

FIGURE 1: Flow cytometry gating scheme Data was gated in the following order:
cells, single cells, live cells Then, live cells were gated for insulin, glucagon, and Ki67
expression, respectively Finally, a double gate was created by gating for Ki67 expression
on top of the insulin gate
ug/uL trypsin inhibitor (Sigma T0256).
a 7% increase in insulin expression
Following a fve-day incubation, islets
(p>0.05), those expressing glucagon
were harvested, dispersed and stained
showed a 1.2% decrease (p>0.05),
for insulin, glucagon, and Ki67 expresand those expressing Ki67 showed a
sion in order to identify β-cells, α-cells
1.6% increase (p>0.05). However, the
and proliferative cell
populations, respec- These data suggest that the pancreatic exocrine
tively. Cells were analyzed by flow cytom- secretome may play a role in regulating islet
etry with the gating
scheme i l lustrated cell phenotype, which may pave a new avenue
in Figure 1. The data
from three separate in T1D therapy via modulating β-cell mass.
experiments were analyzed using unpaired, two-tailed
percent of islet cells expressing both
t-test using Prism software (Figure
insulin and Ki67 following trypsin
2). Compared to islets incubated in
inhibitor incubation was signifcantly
media alone, the percent of islet cells
incubated in trypsin inhibitor, showed
Continued on p. 12

11

Continued from p. 11
increased by 4.4% compared to islet
cells in media alone (p<0.01) (Figure
2). These data suggest that the pancreatic exocrine secretome may play
a role in regulating islet cell phenotype, which may pave a new avenue
in T1D therapy via modulating β-cell
mass. Future studies will explore the
functionality of islets treated in vitro
with exocrine pancreatic secretome.
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Signif icant neurodevelopmental
delay is emerging as one of the
most important current challenges
for patients with congenital heart
disease (CHD). Previous clinical
studies demonstrate that reduced
oxygen delivery due to CHD results
in subnormal brain development.1,2
The piglet brain is a powerful new tool
to study human brain development.
We hypothesize that studies using
the piglet model of chronic cerebral
hypoxia will allow us to understand
the underlying cellular events of
chronic hypoxia in perpetuating
neurodevelopmenta l da mage in
children with CHD.3 This study
aims to evaluate the efect of chronic
hypoxia on piglet brains through
histological, DTI (diffusion tensor
ima g ing ) a nd NODDI (neu r ite
orientation dispersion and difusion
imaging ) ana lyses to determine
the regional diference in the brain
damage in CHD.
Piglets were exposed to either
chronic hypoxia (10.5% O2: H(x)
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group, n=12) or sham-hypoxia (21%
O2: N(x) group: n=12) from P3 to P14.
Six piglets from each group were
euthanized at day 14 (2-week N(x) and
2-week H(x)), and another 6 piglets
from each group were subjected to
grow under normal oxygen conditions
from day 14 to six weeks of age (6-week
N(x) and 6-week H(x)). Brains were
extracted from piglets and examined
using 1) immunohistochemical assays
(Olig2+, CC1, PDGFR-α) to assess
the cellularity alterations in white
matter following chronic hypoxia,
and 2) DTI (including fractional
anisotropy (FA), axial diffusivity
(AD), radial diffusivity (RD), and
mean difusivity (MD) images) and
NODDI (includ ing N DI, ODI,
and KAPPA images) neuroimaging
techniques.1,2 MRI-based piglet
brain atlases were applied on DTI
and NODDI images to evaluate
structural differences between Hx
and Nx brains.
Two-week Nx brains revealed a
significant increase in the density
of CC1-positive cells compared to
2-week Hx brains in white matter.
A significant increase of fractional
anisotropy (FA) intensity was also
obser ved in the peripheral white
matter of Nx brains compared to Hx
brains at 2 weeks (Figure 1). Although
the diferences of FA intensity in the
peripheral white matter disappeared
between Nx and Hx at six weeks,
central deep white matter revealed a

signifcant decrease in FA intensity in
Hx brains vs Nx brains at six weeks.
Radial diffusivity (RD) mapping
demonstrated a signifcant increase in
the right anterior cortex in 2-week Nx
brains compared to 2-week Hx brains.
Orientation Dispersion Index (ODI)
mapping also revealed a signifcant
increase in central white matter
regions between two weeks Nx and
Hx (Figure 2). KAPPA mapping a
significant increase in central gray
matter regions between two weeks
Nx and Hx.
The results reveal diferent cellular
and microstructural alterations after
chronic hypoxia between deep and
peripheral regions in the piglet white
matter. Studies using this model
can provide important data needed
to better interpret human imaging
studies.
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Diffuse midline glioma ( DMG),
including diffuse intrinsic pontine
glioma (DIPG), constitutes up to
20% of pediatric brain cancer and
has a median survival of less than
one year.1 We have identifed a novel
HL A-A*02:01-restricted neoa ntigen epitope encompassing the
H3.3K27M mutation and implemented a pilot clinical trial through
the Pacifc Pediatric Neuro-Oncology
Consortium (PNOC007). Newly
diagnosed DIPG patients who are
HLA-A2+ and H3.3K27M+ underwent
radiation therapy, and then received
the H3.3K27M peptide vaccine and
tetanus toxoid (TT) peptide emulsified in Montanide in combination
with poly-ICLC every three weeks for
a total of 24 weeks.
Our objective is to characterize
vaccine-induced H3.3K27M-specifc
T-cell subpopulations in peripheral
blood mononuclear cells through
the evaluation of surface markers
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FIGURE 1: A multifaceted analysis incorporating patient-specifc myeloid
subpopulation proportions as well as H3 3K27M-specifc CD8+ T-cells was conducted
to elucidate potential trends that may exist between immune composition and
clinical outcomes While not statistically signifcant, patients with less than 25% of
myeloid cells phenotyped as monocytic myeloid-derived suppressor cells (Mgroup)
at baseline were found to have a hazard ratio (HR) of 0 10 (CI = 0 01-1 00, p-value =
0 051) Furthermore, non-statistically signifcant inverse trends between the baseline
proportions of myeloid cells phenotyped as early myeloid-derived suppressor cells
(Egroup) and H3 3K27M-reactive CD8+ T-cells (DexGroup) were observed
correlated with activation, memory,
and exhaustion phenotypes utilizing a

novel H3.3K27M-specifc dextramerbased mass cytometr y method. 2
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Through this approach, the temporal
expansion of vaccine-reactive CD8+
T-cells was observed in all patients (n
= 4) who completed a minimum of 18
weeks of the study. These T-cells were
subsequently stratifed into discrete
clusters on a tSNE plot using canonical
CD8+ T-cell markers. Resultant clusters were further classifed by their
expression profles, revealing distinct
efector memory and exhausted subpopulations. Chronological monitoring of these groups indicates the
time course-dependent development
and persistence of vaccine-reactive
exhausted and efector memory CD8+
T-cells in 75% of patients analyzed.
Fu r thermore, a compa rative
analysis of myeloid subpopulations
revea led a n inverse correlation
between the expansion of monocytic
myeloid-derived suppressor cells
(M-MDSCs) and length of stay on
the vaccine.3 Future plans include the
analysis of regulatory T-cells (Tregs)
and MDSCs of all enrolled patients
to further investigate the relationship
between the length of stay on the study
and prevalence of immunosuppressive populations. This methodology
offers insight into the progression
of vaccine-induced patient immune
responses and exhibits promise as a
platform that may be extrapolated to
other immunotherapies.
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FIGURE 2: A Kaplan-Meier survival curve was conducted to elucidate

the potential clinical implications of monocytic myeloid-derived
suppressor cells (M-MDSCs). Patients were divided into cohorts
containing greater (Mgroup=High) and less (Mgroup=Low) than
25% of myeloid cells phenotyped as M-MDSCs, revealing a trend of
Mgroup=Low experiencing longer overall survival post-diagnosis, though
not statistically signifcant (p-value = 0.085).
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TABLE: PATIENT AND DISEASE CHARACTERISTICS
Characteristics

N = 81

Median age, years (range)

68

Gleason Score
Gleason 6

1

Gleason 7

27

Gleason 8

19

Gleason 9

25

Gleason 10

7

Gleason unknown

2

bone

28

LN

15

viscera

6

White

30

African American

37

Hispanic/Latin American

8

Asian/Pacifc Islander American

3

Native American

1

Declined to answer

2
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2
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Prostate cancer continues to be the
most common non-cutaneous solid
tumor diagnosed in men in the United
States, with 13,000 new diagnoses
among A merican ma le veterans
annually, and is the second leading
cause of death among American male
veterans. 1,2 In an attempt to tailor
treatments to each patient, specifc
mutations have been evaluated in
tumors via targeted next generation
sequencing (NGS).3 Although studies
using NGS in clinically aggressive
prostate cancers have been done in
the civilian population, 4 ,5 similar
studies in veterans have not been performed to date. The purpose of this
study was to characterize the genetic
profiles of prostate cancer among
a veteran population treated at the
U.S. Department of Veterans Afairs
Greater Los Angeles Healthcare
System.
In this retrospective cohort study,
we analyzed NGS data collected
between August 2006 and September
2018. Archival or fresh prostate cancer
tissue from 81 veterans (76 primary
tumors, 5 metastases) underwent targeted sequencing via the Personalis
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Site of metastasis at sequencing

Race

ACE CancerPlus® next generation
sequencing platform. The sequencing
panel covers 181 genes frequently
mutated in cancers. Clinically relevant
genomic alterations were defned as
changes in copy number or mutations
(fusions, deletions, rearrangements,
truncations) within established oncogene/tumor suppressor pathways
such as DNA damage repair (DDR),
PI3K/AKT, p53, MAPK, WNT and
AR regulation. Patient demographic
statistics and frequencies of mutations from the patient samples were
tabulated.
The table presents the baseline
characteristics of 81 prostate cancer

patients in our study. A majority of
patients had Gleason scores between
seven and 10. At time of biopsy, the
median age was 68, with metastases
noted in the bone, lymph nodes, and
viscera. Forty three percent of tissue
samples from primary tumors had
clinically relevant genomic alterations, including 6.2% with activating
mutations in MAPK pathway members (KRAS, ERBB2, or BRAF),
3.7% with somatic mutations in DDR
genes (BRCA2 or ATR), 7.3% with
mutations in TP53 or RB1, 4.9% in
APC, 1.2% in the WNT pathway
(CTNNB1), 3.7% with mutations in
the PI3K/AKT pathway (PIK3R1 or
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AKT1), 3.7% with PTEN deletions,
and 22.2% with alterations involving
an AR regulated gene (SLC45A3 or
TMPRSS) (Figure). Of the fve metastatic tumor samples sequenced, one
had a mutation in TP53 and one had
an ETS gene fusion (Figure).
In this study, we demonstrate
that NGS of prostate cancers in the
veteran population is feasible and
may help facilitate their enrollment
in future precision oncology trials.
Interestingly, only 43% of this cohort’s
tumors had detectable mutations,
which is markedly diferent from other
published data on prostate cancer
where virtually 100% of patients have
a detectable genetic lesion.4 This difference in detected mutations may be
due to genetic lesions that are present,
but not recognized by the Personalis
platform. Additionally, these tumors
may be driven by epigenetic alterations that would require another
approach to elucidate such events.
Lastly, the genetic alterations of veterans’ prostate cancer may be distinct
from those in the civilian population,
and are not readily detected by platforms such as Personalis. Thus, larger
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FIGURE: Each vertical row represents one of 81 patients, and each horizontal row
represents the corresponding detected mutated gene Vertical rows 37, 54, 61, 74, and
80 represent sequenced genes from the fve biopsied metastatic sites while the rest
represent genes from primary tumors

data sets, along with more robust
sequencing platforms, are required for
clarifcation.

3.
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Chordoma is a rare and aggressive
bone sarcoma of the skull base and
sacrum. Due to its indolent nature,
it often presents late into the disease
progression. More than 30% of chordoma patients develop metastases,
and ten-year survival rates remain
approximately 50 - 60%. Though
Although research has been increasingly active in this area to understand
the tumor biology of chordoma, there
are no currently FDA-approved treatments, leaving surgical resection and
radiation as the mainstays of treatment. Introducing The development
of new therapies for chordoma ultimately represents a substantial unmet
medical need.1
We explored ribavirin, an antiviral drug approved to treat hepatitis
C, as a potential therapeutic for
chordoma. This drug was considered
given its prior evidence of anti-tumor
efects against other cancer types and
also due to preliminary data from an
assay indicating ribavirin directly
decreases growth of chordoma cell
lines. Ribavirin is known to target
and inhibit eukaryotic initiation
factor 4E (eIF4E), a regulatory subunit of the eIF4F complex that is
known to be overexpressed in 30%
of all cancers.2 In studies examining
the M A PK pathway, which can
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FIGURE 1: Proliferation assay of treated UCH-1 cells
remove inhibitory control of eIF4EBinding Protein 1 (4EBP1) on eIF4E
via phosphorylation, almost all human
chordomas showed immunoreactivity
to not only eIF4E, but also to its
phosphorylated form (p-eIF4E) and
the phosphorylated form of 4EBP1,
indicating its potential value as a
new target for chordoma treatment.3
However, as ribavirin has multiple
cell targets, we also investigated
DZNeP, a small-molecule inhibitor
of S-adenosylmethionine-dependent
methyltransferase activity. This
includes inhibition of the histone
methyltransferase EZH2, which has
been implicated as a driver in a myriad
of cancer types. Ribavirin also has
been demonstrated to inhibit EZH2;
we investigated the therapeutic potential of ribavirin and DZNeP in parallel
in order to explore the comparative
effectiveness of multiple potential
targets in chordoma.4
Sacral and clival chordoma cell
lines (U-CH1 and UM-Chor1, respectively) were utilized for in vitro experiments and treated with DZNeP
and ribavirin in various micromolar
concentrations. U-CH1 was assessed
for cell growth via Cell Counting Kit
8 and proliferation assays, where cells

were manually counted over three
timepoints. UM-Chor1 was assessed
for cell death (apoptosis) via f low
cytometry with AnnexinV (AnnV)
and Propidium Iodide (PI) staining.
AnnV+/PI- staining indicates early
apoptosis; AnnV+/PI+ indicates late
apoptosis. Additionally, clonogenic
assays were performed in both cell
lines.
In proliferation assays of the
U-CH1 cell line treated with ribavirin
or DZNeP, a visible trend of steadily
lower cell count over eight days for
both ribavirin and DZNeP-treated
cells was shown seen (Figure 1). Flow
cytometry in the UM-Chor 1 cell line
demonstrated a signifcant increase
in the number of AnnexinV+ cells
for those treated with DZNeP, and a
trend toward apoptosis in cells treated
with ribavirin (Figure 2). Clonogenic
assays showed a trend toward decrease
in clonogenic potential of U-CH1 but
not UM-Chor1 cells when treated
with ribavirin, while a decreased clonogenic potential was demonstrated
in both cell lines when treated with
DZNeP.
The use of ribavirin may present
some currently mixed results in
efectiveness against chordoma, but
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this warrants further investigation
as monotherapy and in combination
therapy regimens with other treatment modalities, including radiation.
The promising preliminary results
using DZNeP imply that its targets
may be a viable means for chordoma
treatment. Further investigation into
DZNeP through in vivo experiments
may provide evidence pivotal for the
treatment of this devastating cancer.
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Immune checkpoint blockade (ICB)
has shown outstanding clinical success in the treatment of melanoma;
however, a signifcant proportion of
patients develop resistance or do not
respond to ICB.1 New focus has been
placed on improving the efcacy of
ICB through the inclusion of molecularly targeted agents such as histone
deacetylase 6 inhibitors (HDAC6is).
Histone deacetylases (HDACs) are
important epigenetic modulators
of gene expression that have been
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FIGURE 1: Functional characterization of next-generation HDAC6 inhibitors in
comparison to Nexturastat A SM1 Cells were cultured and treated with inhibitor ranging
in concentration from 0 1 mM-25 0 mM for 24 hours (a) HDAC6i potency was quantifed
using the HDAC-GloTM I/II Assay (b) Compound cytotoxicity was evaluated using the
CellToxTM Green Cytotoxicity Assay (c–d) Cells were lysed in RIPA buffer with 1X protease
and phosphatase inhibitor for the evaluation of inhibitor specifcity by immunoblot
Acetylated turbilin and histone 3 expression were analyzed by densitometry
identified as prime cancer therapy
ta rgets. HDAC in hibitors have
already shown signifcant anti-cancer
efects through a primarily cytotoxic

function;2 however, recent studies also
suggest that some inhibitors take on
Continued on p. 20
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a non-canonical role as modulators
of immune-regulated signaling pathways.3 For example, highly selective
HDAC6is, including Nexturastat A
(Next A), are able to heighten tumor
immunogenicity and immune surveillance by modulating the expression
of a variety of immunoregulatory
proteins and shaping the infammatory status within tumor microenvironments.3 These non-canonical
f unctions ma ke HDAC6is idea l
compounds for the potentiation of
immunotherapeutic agents. This
study characterizes the functional
properties of three next-generation
HDAC6is in comparison to NextA,
as well as their non-canonical actions
related to immune-regulated pathways and other non-cytotoxic cellular
functions. Additionally, we aim to
complement functional characterization with in vivo and ex vivo studies
to determine anti-tumor activity in
syngeneic melanoma models.
Three next-generation HDAC6is
(SS-5-54, SS-5-55, SS-5-56), were compared to NextA at concentrations
from 0.1 µM to 25 µM over 24 hours
in vitro using murine melanoma SM1
cells. The potency and cytotoxicity
of these inhibitors were quantified
through HDAC - Glo™ I/ II a nd
CellTox™ Green Cytotoxicity assays,
respectively. Immunoblotting was
used to assess specifcity with acetylated tubulin as a positive readout
and acetylated histone 3 as a negativeunspecific readout. Highly specific
HDAC6is were further evaluated
for anti-tumoral activity and immunomodulatory effects in vivo using
SM1 tumor-bearing C57BL/6 mice
challenged with HDAC6i, αPD1,
and combination therapy. Tumors
were observed over 2 weeks, and subsequently resected, processed, and

;;::
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FIGURE 2: Compound SS-5-55 functions as an immunological agent
analyzed using fow cytometry against
a comprehensive immune cell surface
marker panel.
We found that SS-5-55 best demonstrated characteristics of an ideal

1c & d). This specifcity refects an
essential characteristic of selective
HDAC6 inhibition consistent with a
non-canonical, immunomodulatory
function. SS-5-55 demonstrated a 14.1-

Our results support the characterization of SS-5-55 as a minimally
cytotoxic, selective HDAC6i that functions as an immunological
priming agent capable of potentiating αPD1 immunotherapies.
HDAC6 inhibitor with selectivity
comparable to NextA. SS-5-55 exhibited signifcant potency beginning at
low concentrations (2.5 – 5 µM) (Figure
1a), while maintaining low cytotoxicity above 10 µM where NextA
becomes exceed ing ly c y totox ic
(Figure 1b). Densitometric analysis
of Western blots revealed that SS-5-55
increased acetylation of α-tubulin
in a dose-dependent fashion, but
not acetylation of Histone 3 (Figure

fold increase in acetyl-α-tubulin at 10
µM, whereas NextA led to a 7.2-fold
increase.
Tumor-bea ring m ice treated
with a combination of αPD1 and
SS-5-55 showed significant reduction in tumor volume compared to
individual therapies alone (data not
shown). Combination therapy also
demonstrated significant changes
in the tumor microenvironment,
exhibiting an increase in infltrating
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cytotoxic T-cell and natural killer
T-cell composition, as well as cytotoxic T cell efector memory (Figure
2). Furthermore, combination therapy
and SS-5-55 therapy alone demonstrated a signifcant increase in M1/
M2 macrophage phenotype ratio;
pro-tumorigenic M2 macrophages
were significantly reduced, while
pro-infammatory M1 macrophages
persisted.
Our results support the characterization of SS-5-55 as a minimally cytotoxic, selective HDAC6i

that functions as an immunological
priming agent capable of potentiating
αPD1 immunotherapies. Further
studies are needed to elucidate the
compound’s specific mechanism of
action.

2. Bose P, Dai Y, Grant S. Histone
deacetylase inhibitor (HDACI)
mechanisms of action: emerging
i n s i g ht s . P h a r m a c o l T h e r.
2014;143(3):323-336. doi:10.1016/j.
pharmthera.2014.04.004
3. Knox T, Sahakian E, Banik D,
et al. Selective HDAC6 inhibitors improve anti-PD-1 immune
checkpoint blockade therapy by
decreasing the anti-infammatory
phenotype of macrophages and
down-regulation of immunosuppressive proteins in tumor cells.
Scientifc Reports. 2019;9(1):6136.
doi: 10.1038/s41598-019-42237-3.
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Sensitivity of Malignant B-Cell Lines to PI3KD Inhibitors
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With an estimated 117,470 new cases
of B-cell malignancies in the United
States in 2016, B-cell malignancies
are currently treated with phosphoinositide-3 kinase delta (PI3KD)
inhibitors, such as idelalisib, a p110δ
isoform-specific PI3K inhibitor. 1,
2
Idelalisib, in combination with
rituximab, is US FDA approved for
the treatment of relapsed or refractory chronic lymphocytic leukemia
(CLL). 3 However, despite idelalisib
being an effective treatment for
B-cell malignancies, 28% of patients
are resistant to idelalisib therapy. 2
The mechanism of this resistance is
unknown. Our laboratory’s proposed
mechanism of resistance is aberrant
over-expression of the short isoform of PI3KD (PI3KCD-S), formed
through alternative RNA splicing
(AS) in idelalisib-resistant patients.
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FIGUREC1: P110δ-S kinase activity is resistant to new PI3K inhibitors copanlisib and
buparlisib a The long isofor exhibits does-dependant sensitivity (inhibition) to currently
available PI3K inhibitors used clinically to treat B-cell malignancies, including copanlisib
and buparlisib b The short isoform is resistant to currently available PI3K inhibitors,
including copanlisib and buparlisib
AS is a cellular post-transcriptional
regulatory process that produces
alternative mRNA transcripts, which
encode distinct protein isoforms. 4
We hypothesize that a higher ratio of
short to long (S/L) isoforms of PI3KD

is associated with greater resistance
to idelalisib.
Previous cell-free kinase assays
in our laboratory have demonstrated
Continued on p. 22
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that the recombinant short PI3KD
isoform, but not the long isoform
(PI3KCD-L), is resistant to the PI3KD
inhibitors idelalisib, umbralisib, and
duvelisib. We tested two additional
PI3KD inhibitors, copanlisib and
buparlisib, recently shown to be efective in treating B-cell malignancies.
Both inhibitors were likewise inefective in reducing activity of PI3KCD-S,
while potently inhibiting activity of
PI3KCD-L.

and Maver cells showed greater sensitivity to idelalisib, while JeKo-1 and
JVM-2 showed greater resistance to
idelalisib. These results suggest that
the expression level of PI3KCD-S
may have an important role in conferring varying degrees of resistance to
PI3KD inhibitors.
With these results, we correlated
these varying degrees of resistance to
idelalisib with S/L expression ratios
measured by RT-PCR. Malignant
B-cell lines JeKo-1 and JVM-2, the
two cell lines that were resistant to

acquired resistance in patients with
B-cell malignancies.
In the future, we aim to accomplish two additional tasks: 1) employ
CRISPR to knock-out the PI3KD
gene in malignant B-cell lines followed
by ectopic over-expression of either
the long or short variants of PI3KD,
and 2) procure retrospective human
patient specimens to measure the S/L
expression ratio of PI3KD and correlate these fndings to idelalisib resistance. We hypothesize that patients
displaying resistance to idelalisib will
present with malignant specimens
exhibiting a high S/L expression
ratio of PI3KD. Conversely, patients
displaying sensitivity to idelalisib will
present with malignant specimens
exhibiting a low S/L expression ratio of
PI3KD. These fndings emphasize the
role of PI3KCD-S in B-cell malignancies resistant to PI3KD inhibitors and
the necessity for precision medicine in
the clinical setting to improve therapy
for patients with B-cell cancers.
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the apoptotic and anti-proliferative
efects of idelalisib, exhibited higher
S/L ratios, while the two cell lines that
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In the United States, approximately
45% of pregnancies are unintended,
which is among the highest rates
i n the developed world. L ongActing Reversible Contraceptives
(LARC) are the most efective form
of contraception a nd therefore
are a cr ucia l piece of achieving
reproductive health equity for lowincome popu lations. 1 Med ica id
covers approximately 19.4 million
low-income women of childbearing
age ( WCBA), and this benefit is
required to cover family planning
services without restrictive prior
authorizations or cost-sharing. 2, 4
In non-Medicaid expansion states,
m a ny WC BA on l y q u a l i f y for
Medicaid after becoming pregnant
and subsequently lose this coverage
60 days after delivery. As such, women
who would like to start a LARC
method would benefit from that
method being available to them
in the hospital after delivery and
prior to discharge. This is called
postpartum LARC insertion, which
is a safe and highly efective method
of contraception recommended by the
American College of Obstetrics and
Gynecology.1 Despite the perceived
benefts of this insertion method, it
is under-utilized among the Medicaid

Device

Insertion

Part of Global Payment

Separate Payment

Part of Global Payment

Part of Global Payment

Separate Payment

Separate Payment

Separate Payment

Part of Global Payment

No Data Collected

FIGURE: Variation in Medicaid Postpartum LARC Insertion Coverage by State2,4 Policies also
reviewed from individual state medicaid agency websites

population and presents an enormous
opportunity for policy improvement.
Barriers to postpartum LARC
insertion exist at the state, health
plan, provider and patient levels. The
devices are expensive to stock and
often poorly reimbursed by insurance
carriers. The Center for Medicaid
Services (CMS) has provided guidance
on postpartum LARC insertion recommending that it be unbundled from
the global maternity payment, but
each state has the autonomy to make
its own policies. Coverage policies also
depend on factors such as state distribution of Medicaid through Managed
Care of a Fee for Service Model or state
expansion of Medicaid through the
Afordable Care Act.

CLINICAL PRACTICE INNOVATION AND PUBLIC HEALTH/POLICY

This research project evaluated the
language that State Medicaid Agencies
used in describing their LARC policies and postpartum LARC access
in particular in order to evaluate the
variation that exists across states.
The biggest variation in language
regarded if the insertion procedure
and the device itself were reimbursed
separate from the global maternity
payment as recommended by CMS.
The results are highlighted in the map
created in Figure 1.2,4 The majority
of states do reimburse for the LARC
device or insertion outside of the
global payment. However, little correlation could be found among state
Continued on p. 24
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Continued from p. 23
political preference, demographics, or
Medicaid distribution method.
A l iterat ure rev iew revea led
evidence from two states demonstrating that after an unbundling
policy change was implemented, more
patients did receive LARC devices in

racism. Many of these issues still exist
today creating distrust of LARC in
these communities.1 The goal of any
policy would be to create an environment where women can choose their
preferred method of family planning,
while recognizing that unique barriers
to LARC also need to be addressed.
In conclusion, this research is only a

When thinking about reproductive health policy, it is equally important to acknowledge the historical context where black and poor
women are frequently victims of reproductive coercion, forced sterilization, and racism. Many of these issues still exist today creating
distrust of LARC in these communities.1
the immediate postpartum period.3,5
The policy review also highlighted
unique innovations to payment barriers. For example, the state of Texas
contracts with specialty pharmacies
that bill Medicaid directly and ship
LARC devices to providers to avoid
high upfront costs.2
When thinking about reproductive health policy, it is equally important to acknowledge the historical
context where black and poor women
are frequently victims of reproductive
coercion, forced sterilization, and

24

small piece of the puzzle in terms of
improving reproductive equity for
all women. More research needs to
be done to better understand what
policy innovations will improve access
to LARC among WCBA receiving
Medicaid while preserving reproductive equity. In the short-term however, unbundling LARC device and
insertion from the global maternity
payment may be an easy frst step.
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Group
Size

Relative MIPS
Percentile
(Percentage Score)

PI
Non participation
($)

PI
Incentive
($)

POMP Query
Incentive ($)

Ind ividual
(1)

25th to 50th (37%)

(580)

95

15

75th (85%)
Small
(2-15)

(0%)

50th (37%)

1

T he u nce r t a i nt y s u r r o u nd i n g
Medicare Quality Payment Programs
(QPP) such as the Merit Based
Incentive Payment System (MIPS)
has forced many organizations to
strategize on how to achieve success
under value-based payment systems.
Originally promised larger payment
incentives than received, many provider groups are questioning the efectiveness of MIPS in achieving stated
policy goals. At present, the MIPS
score measures a provider organization’s performance in four key areas:
quality, cost, promoting interoperability (PI), and improvement activities.1 The subsequent score received
forms the basis for a negative, neutral,
or positive Medicare Part B payment
adjustment as shown in Figure. With
the goal of investigating these trends
and their implications for public
policy moving forward, a financial
model was created to predict the
extent of PI participation for organizations of varying sizes. This model
specifcally analyzed the feasibility of
PI measures because they are among
the most capital-intensive measures
and thus most useful in elucidating
group decision-making. Ultimately,
we sought to determine whether
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Medium
(16-99)

400

1,800

230

(37,000)

NIA

NIA

(4, 100)

670

80

75th (85%)

2,800

13,000

1,600

25th (37%)

(24,000)

4,000

500

50th and up (85%)

17,000

75,000

9,700

Large (100 +)

25th and up (85%)

40,000

180,000

23,000

Very Large
(500 +)

25th and up (85%)

200 ,000

890,000

120,000

TABLE: Financial Incentives by Group Size and Percentile Performance. This
table summarizes the incentives and fnancial penalties for varying levels of compliance
with MIPS measures as determined by the fnancial model PI Nonparticipation is the
Medicare payment adjustment received if the group decides to report a zero for PI
measures to CMS PI Incentive is the Medicare revenue gain if the group participates in
PI to the percentage score of their respective percentile of overall MIPS performance
The PDMP Query incentive is the revenue gain if the group decides to pursue the 5
bonus points by searching a state PDMP database before prescribing an opioid
Centers for Medicare and Medicaid
Services CMS incentives were likely
to be efective in achieving their goals
and the ramifcations of the incentives on the United States health care
system as it transitions to value-based
care.
Solo, small, medium, large, and
very large practices were modeled
using available data and final rules
published by the US Department of
Health and Human Services (HHS).1
MIPS payment adjustment projections were extrapolated for the range
of possible MIPS scores as shown in
Figure. The approximation of group
MIPS performance under varying
conditions was performed using
quartile MIPS performance data
generated from a sample distribution
of approximate MIPS scores.2
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The resulting fnancial incentives
for MIPS participation are shown
in Table. MIPS incentivizes performance proportionally, and as a result,
the scale of operations is critical to
the fnancial viability of compliance.
Larger groups have a greater capacity
to implement operational changes
and make capital investments due to
their fnancial leverage and advanced
organizational structure. Also, larger
groups likely have dedicated clinical
leaders, more sophisticated electronic
health record support, and contracts
with experienced consultants to
ensure maximal compliance with
MIPS objectives. Small groups may
not have the capital nor dedicated
administrators to comply fully with
Continued on p. 26
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Continued from p. 25
MIPS objectives, placing them at a
disadvantage. Rather than invest in
technological solutions to advance
their health care practice, smaller
organizations are more likely to
maintain fnancial viability through
non-compliance.
Our analysis demonstrates that
current MIPS policy creates a “reverse
Robin Hood” efect whereby larger
groups gain additional Medicare
revenue on the backs of lower performing, smaller groups. These larger
groups inevitably absorb smaller
groups that cannot survive under
these conditions, making MIPS
policy an efective force of consolidation in the health care marketplace. It
is conceivable that a long run goal of
MIPS was to encourage consolidation
so entities would be more responsive
to policy changes in the future. In this
way, MIPS may lead to an increase
in overall health care quality in the
U.S. health care system through the
adoption of CMS value-based measures. Another goal may have been
to encourage the creation of large
entities capable of assuming fnancial
risk in order to lower total Medicare
expenditures. While the QPP valuebased payment system is still in its
infancy in the United States, current
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FIGURE: Projected Payment Adjustments by MIPS Score for PY2019 [1]. CMS
projections for the base incentive (1 11%) and exceptional performance bonus (3 58%)
were distributed among the range of MIPS scores possible in the model to predict
Medicare Part B incentive payments as a function of MIPS score received
policy may also be incentivizing a provider market with less competition.

REFERENCES
1.

U.S. Department of Health & Human Services, Centers for Medicare and Medicaid
Services. Medicare Program; Revisions
to Payment Policies Under the Physician
Fee Schedule and Other Revisions to Part
B for CY 2019; Medicare Shared Savings
Program Requirements; Quality Payment
Program; Medicaid Promoting Interoperabilit y Program; Qua lit y Payment
Program-Extreme and Uncontrollable
Circumstance Policy for the 2019 MIPS
Payment Year; Provisions From the Medicare Shared Savings Program-Accountable
Care Organizations-Pathways to Success;

and Expanding the Use of Telehealth
Services for the Treatment of Opioid Use
Disorder Under the Substance Use-Disorder Prevention That Promotes Opioid
Recovery and Treatment (SUPPORT)
for Patients and Communities Act. (2018).
Available from: w w w.federalregister.
gov/documents/2018/11/23/2018-24170/
medicare-program-revisions-to-payment-policies-under-the-physician-feeschedule-and-other-revisions
2. U.S. Department of Health & Human Services, Centers for Medicare and Medicaid
Services, Quality Payment Program. 2017
Quality Payment Program Experience
Report Appendix. (2019). Available from:
qpp.cms.gov/about/resource-library

Fusion | 2020

Web-Based Quality of Life Data Collection:
A Review in Radiation Oncology
Ian Messing,
MSII
ADVISORS: Yuan
J Rao, MD,1 Sharad
Goyal, MD,1 Martin
Ojong-Ntui, MD1
The George
Washington University School of Medicine and
Health Sciences
1

Radiation oncology (RadOnc) providers regularly incorporate quality
of life (QoL) assessments into their
practice to assess treatment toxicities
and late efects of therapy. However,
routine QoL assessments may burden
patients and providers and disrupt
clinical workflow.1 Electronic QoL
assessment systems mitigate obstacles
to collecting and analyzing patient
data, such as poor handling of paper
forms, transcription errors, and lack
of validation checks.2 Electronic collection systems provide an efficient
and convenient means to the same
end. To maximize efectiveness, these
platforms must be implemented in a
logical manner and emphasize protection of patient information. In this
abstract, we outline our method for
designing and implementing a webbased QoL questionnaire and repository in our RadOnc clinic.
Our institution provides Research
Electronic Data Capture (REDCap)
to easily build online surveys and
databases.3 REDCap is a noncommercial, secure, and HIPAA-compliant
web-based platform. This fast, fexible
program can be used to export data to
common data analysis packages and
create custom ad hoc reports.
O u r i nstit ution uti l izes the
EORTC Quality of Life Group’s

~

"EORTC QLQ • H&N35 "

When the following swvey is completed:
-EORTCQLQ - C30 (version

Jr

AND •

Activated

~

When the following logic becomes true:
E
selection] =~6(e.g., [age]> 30 and [gender]=

._ _____

__________

____

~

·n

rest
_ klg
_:_~ _,.,_th a record - select record - .-

FIGURE 1: Surveys were queued based on the designed branching logic In this
instance, H&N35 would be queued upon completion of QLQ30 and upon selection of
“Subsequent Follow-Up QoL Head and Neck Cancer” (initial selection 6) by the team
member
core questionnaire, the EORTC
QLQ-C30 (QLQ30), and site-specifc
modules to assess QoL of patients who
received treatment for head and neck
cancer (HNC), endometrial cancer,
and cervical cancer. The EORTC
QLQ-H&N35 (H&N35) is a widely
used tool to measure QoL in HNC
patients and has been validated in
large-scale studies.4,5 We recreated a
version of both the QLQ30 and the
H&N35 in REDCap.
The project was designed using
longitudinal data collection. Due
to variations in type and frequency
of patient encounters, we define
events by patients’ unique medical
record numbers (MRN) and type of
encounter. Combined with the assessment date, we can analyze patient
encounters over time.
A team member initiates patient
encounters by accessing REDCap,
providing the patient’s MRN, and
selecting the visit type. To access
the H&N35, team members indicate
that they are preparing a subsequent
follow-up visit for an HNC patient.
The project is designed with
branching logic to queue a validation survey. We included this step
to authenticate the response collection and to familiarize patients with
the platform. Upon completion, the
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patient will be presented with the
QLQ30 and then the H&N35.
The project was designed to reduce
patient decision-making and efort.
Along with branching logic (Figure
1), survey sections are displayed as
matrices of felds and separated over
different web pages when answer
choices or response prompts change
(Figure 2). This design was implemented to limit patient confusion
and promote data quality. Data validation techniques are also employed
to ensure appropriate completion of
each survey.
After checking in at our clinic, a
team member escorts the patient to
an examination room, accesses the
project in REDCap, enters initial
patient information, and selects the
visit type. Next, the team member
assesses the completion of the initial
validation survey and the frst questionnaire is selected and opened. The
patient uses a laptop computer to
complete the QoL surveys queued in
the web-browser.
Development of a simple and
effective web-based platform for
survey administration presents many
challenges. The REDCap program
facilitated this objective by enabling
Continued on p. 28
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During the past week :

efcient administration of web-based
surveys. The QLQ30 and H&N35
were foundational starting points
upon which to expand our platform
and assess other treatment sites.
Given the simplicity of the REDCap
platform, we have successfully administered surveys on tablet computers
and aim to expand their utility.

No

Have you used pain·killers?
Have you taken any nutritional
supplements (excluding vitamins}?
Have you used a feeding tube?

reset
Have you lost weight?
ceset

Have you gained weight?

reset

FIGURE2 : Matrix felds were utilized to limit patient confusion and promote data
quality and compliance This was achieved by grouping items with similar prompts and
responses
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Interpersonal communication has
been drastically altered due to innovations in technology.1 Emojis are
currently an undeniable part of the
world’s communication language
and are utilized by 92% of the online
population. 2 They represent emotional and personality nuances which
would be present in face-to-face communication.3 We sought to determine
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10

FIGURE: Ten different emoji faces
whether emojis may be a tool that can
efectively and efciently evaluate a
patient’s mood in a busy emergency
department (ED) setting.
This was a prospective study
performed at the ED of an urban
academic center. Patients 18 years of

age or above with lower acuity level
at arrival (an Emergency Severity
Index (ESI) between 3 and 5) were
prospectively enrolled. Upon arrival
to the ED, a screen with 10 different emoji faces ranging from one
(extremely satisfied, smiling face)
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to 10 (extremely dissatisfed, angry,
red face) was given to each patient
(Figure). Every 30 minutes after their
arrival, patients were asked to identify
their emotional state by selecting one
mood-determining emoji. The change
in emojis throughout the patient’s
visit was recorded. The patient’s age
and length of stay (LOS) were examined to assess the effect that these
variables may have had on the patient’s
frst and last selected emoji, and the
change between the two. The analysis
included time series, Spearman correlation, multiple linear regression,
categorical, nonparametric statistics
and McNemar-Bowker Test of symmetry for paired emoji data.
The study included 348 patients
with valid emoji data. On the emoji
scale, the mean emoji upon arrival
to the ED and upon discharge were
5.8 and 5.3 respectively (P=0.0004;
Wilcoxon signed rank test), showing
significant improvement in patient
mood. When the patients frst arrived
at the ED, 7% and 9% of the patients
selected emoji #1 and emoji #10,
respectively. Upon discharge, 10%
and 9% of the patients selected emoji
#1 and emoji #10, respectively. About
32% of the patients did not change
their emoji during their ED visit.
About 30% exhibited improvements
in their mood and a few displayed
worsening mood (25%). The length
of stay in the ED was not correlated
to the change in emoji (P=0.11). The
patient’s age also did not have an efect
on the change in emoji (P=0.64). The

Characteristics

No. (%), Average

Admission to ED
First mood-determining emoji

5 8+2 7

Emoji #1 selected

26 (7 4)

Emoji #10 selected

30 (8 6)

Mood-determining emoji for males

5 4+2 6

Mood-determining emoji for females

6 2+2 6

Discharge from ED
Last mood-determining emoji

5 3+2 8

Emoji #1 selected

36 (10 3)

Emoji #10 selected

32 (9 2)

Changes in Mood
No change in mood

112 (32 2)

Improved mood

104 (29 9)

Worsened mood

88 (25 3)

TABLE: Patient mood in the ED from admission to discharge
mean emoji at admission for male
patients was signifcantly lower than
those for female patients (5.4+2.6
vs. 6.2+2.6; P=0.006) and males displayed a slightly higher mood change
(slope=0.52; P=0.065; Table).
It is difcult for healthcare providers to ascertain a patient’s emotional state to better assess how they
are feeling about their medical issue
or ED experience. Identifying tools
that can improve this more nuanced
but important aspect of emergency
care could be useful. Our study has
illustrated that emojis can be a useful
tool in tracking a patient’s mood
during the ED visit. Patients are very
familiar and comfortable with emojis,
so their use requires little explanation.

CLINICAL PRACTICE INNOVATION AND PUBLIC HEALTH/POLICY

Emoji assessments are very quick and
simple to perform and have the potential to impact overall management in
the ED.
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Children with medical complexity
(CMC) are children whose health
care status encompasses four main
areas: chronic, severe health conditions; substantial health service needs;
functional limitations, which are
often severe; and high health resource
utilization. Examples of children with
medical complexities include, but
are not limited to, those with congenital heart disease, cerebral palsy,
spina bifda, sickle cell disease, and
HIV/AIDS.1 These patients require
individualized care, often involving
round-the-clock caretakers who
ensure adherence to multiple medications, address specifc dietary and
feeding needs, and understand how
to use medical technology associated
with each patient’s condition. Such a
high level of care may place a larger
burden on parents of CMC than is
feasible. Under these circumstances,
medical foster care services provide
additional support for families with
medically complex children.2
Second Family is a non-profit
organization with medical homes
throughout Maryland that house
many of these CMC in the medical
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foster care system. Once patients
through a literature review on
enter Second Family, they receive
the needs of CMC, consultations
pr i m a r y ca re ser v ices t h roug h
with Complex Care pediatricians,
C h i ld r e n’s Na t ion a l Ho s pit a l
and observation of patient(Children’s National). However, in
provider and caretaker-provider
establishing this transfer of care,
interactions during Complex
patients and their Second Family
Care visits at the Child Health
caretakers often arrive at appointCenter and Adolescent Health
ments without adequate knowledge
Center.
of patients’ medical and social back➤ 3) Study: We collected feedback
ground and needs. These information
on the checklist through focus
gaps create significant challenges
groups of stakeholders (parents
for clinical providers when making
and caretakers of Second Family
medical decisions. In order to reduce
patients, the Pediatric Medical
these gaps, improve each provider’s
Specialist at Second Family,
care for Second Family patients, and
Complex Care Team social
foster collaboration between Second
workers, case managers, nurses,
Family and Children’s National, we
and physicians).
created a checklist for Second Family
caretakers to use to prepare for each
➤ 4) Act: We revised the checklist
patient’s appointments.
until we reached a fnal product.
We approached this
project using the “PlanWe approached this project using the “PlanDo-Study-Act”(PDSA)
cycle, a quality improveDo-Study-Act” (PDSA) cycle, a quality improvement tool created as
part of the Institute
ment tool created as part of the Institute for
for Healthcare’s Model
for Improvement. This
Healthcare’s Model for Improvement.
cycle involves creating a
plan or initiative and colThrough implementation of this
lecting the necessary data (plan), testing
checklist, we not only aim to improve
the plan or initiative (do), studying the
the Complex Care Team’s ability to
testing results (study), and then refning
care for Second Family patients, but
the initial plan accordingly (act). Our
also intend to educate Second Family
project was designed as follows:
caretakers regarding what informa➤ 1) Plan: To develop a standardized
tion they need bring to healthcare
clinical checklist for complex
visits. We hope that our checklist will
care visits with Second Family
serve as a tool or template for other
patients at Children’s National.
measures of standardizing care among
➤ 2) Do: We identifed important
children with medical complexities
elements for the checklist
and their caretakers, families, and
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providers. This tool may also be
expanded and externally validated
via use in other populations, such
as Second Family patients visiting
Children’s National’s Emergency
Department, foster families with
CMC not in a group medical home,
adults with medical complexities, and
general primary care visits.
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The advent of telehealth services
has been a critical turning point in
healthcare delivery that has been
expanding access, reducing costs, and
improving health outcomes. Under
the current fee-for-service Medicare
payment model, telehealth coverage
is limited to rural areas, which are
defned as health professional shortage
areas, to reduce over utilization
and keep costs down. 1 A recent
study showed that telemedicine
ut i l i z at ion i n r u r a l Me d ic a r e
populations, particularly for mental
health, complemented healthcare
management, but did not increase
utilization.2 Moreover, factors such as
geographical restrictions on telehealth
coverage may be impeding the growth
of telehealth. Others argue that
expanding telehealth service coverage
may increase utilization and drive up
healthcare costs.1,3 While these are

visits as the primary outcome and
valid points, the impact of telehealth
outpatient visits as well as patient
on overall healthcare utilization
portal interactions as covariates.
patterns is not well understood in the
Results show that there was a
Medicare population. The University
significantly smaller percentage of
of California, San Francisco (UCSF)
telehealth patients that utilized the
is a quaternary care center that is
ED versus non-telehealth patients in
uniquely positioned in that it has
both clinics (40% vs. 48%, respectively,
consistently offered telehea lth
for Symptom Management Clinic
to all patients regardless of payer
status. Thus,
Our fndings indicate that telehealth utilization is
ma ny Med ica re
patients who utilize
associated with an overall decrease of ED utilizaUCSF’s telehealth
a r e n ot co v e r e d
tion in the Medicare population. However, the
for telehealth
s e r v ice s . I n t he
current study, we
relationship between telehealth use and other
determined if there
was a relationship
utilization patterns (e.g. clinic visits, emails) is
between telehealth
utilization a nd
likely confounded by variables such as the undero v e r a l l h o s p it a l
utilization in
lying disease and technological literacy.
the Medicare
p o p u l a t i o n a t U C S F. S u b s e t
and 11% vs. 24%, respectively, for
analyses on Medicare patients was
Endocrinology Clinic). We used a
performed using data from two of the
Poisson regression to model our data
highest utilizing telehealth clinics:
and it showed that the incidence
Symptom Management Clinic and
rate of ED visits among telehealth
Endocrinology Clinic. To determine
users (IRR, 95% CI) is signifcantly
if telehealth services among Medicare
less than that among non-telehealth
patients was associated with decreased
hospital utilization, we used ED
Continued on p. 32
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Continued from p. 31
users in the Symptom Management
Clinic and Endocrinology Clinic
(0.78 and 0.52, respectively). There
was heterogeneity in the relationship
between telehealth visits and ofce
visit patterns, with the Symptom
Management Clinic demonstrating
equivalent office visit utilization
between telehealth and non-telehealth
users while the Endocrinology Clinic
showed a slightly greater percentage of
telehealth users who had ofce visits
compared to non-telehealth users
(99.1% vs. 97.5%, respectively). Lastly,
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telehealth users had significantly
more patient portal interactions
on average when compared to nontelehealth users in both clinics. Our
findings indicate that telehealth
utilization is associated with an
overall decrease of ED utilization in
the Medicare population. However,
the relationship between telehealth
use and other utilization patterns
(e.g. clinic visits, emails) is likely
confounded by variables such as the
underlying disease and technological
literacy. Future studies are needed
to better understand the impact of
telehealth on overall care utilization.
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Low-income countries are facing
the double burden of communicable
diseases and rising prevalence of
noncommunicable diseases (NCDs).1
Traditionally, community health
workers (CH Ws) have played a
signifcant role in the prevention and
control of communicable diseases
such as malaria, tuberculosis, and
HIV. 2 However, the involvement
of CHWs in NCD prevention and
control has not been fully explored,
especially in many Low- and MiddleIncome Countries (LMICs) including
Uganda. 3 This direct participant
observational study examines how
well CHWs receive, comprehend, and
engage with Omni Med’s hypertension
quarterly training. Omni Med is a
non-profit organization working
to reduce global health inequity
in developing countries through
innovative programs focused on
communit y education, building
sustainable solutions, and health

volunteerism. CHW demographics
and contacts were obtained from
Omni Med. Starting August 2019,
CHWs were invited for a day-long
training targeting hypertension risk
factors such as the effects of highstress levels, alcoholism, and excess
carbohydrate consumption. After
each training, CHWs were assessed
on their understanding of the topics
and given the opportunity to ask
questions and brainstorm solutions.
Their responses were collated and
used to cater future sessions to their
goals, concerns, and knowledge base.
Since the implementation of the
training, 269 CH Ws have been
trained. Dialogues and brainstorming
sessions with CHWs demonstrated
that they grasped the effects of
diet, alcohol, and stress on blood
pressure a nd agreed that these
three rampant risk factors existed
in their villages given the state of
widespread poverty. 4 From these
dialogues and brainstorming sessions
emerged three key themes which
afrmed the CHWs comprehension
and engagement with the training
material. First, CHWs provided
further points of discussion on the
causes of hypertension and frequently
brought up other chronic NCDs like
diabetes and their relationship to
hypertension. Second, they provided
insight into some of the physical
and mental health misconceptions
that exist within their communities.
For example, some CHWs seemed
to think that certain home-brewed
alcohol is “good for you,” so we have
tried to clarify this by dispelling
the misconception and educating
them on the health consequences
of all kinds of alcohol. Third, they
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have demonstrated a willingness
to spa rk ch a n ge for i mproved
health outcomes through education
and health promotion measures.
Relatedly, CHWs suggested that
male CHWs should talk with male
community members and females
CH Ws w ith fema le communit y
members to promote a more trusting
environment of mutual understanding
with sensitive topics. After the
training, CHWs exhibited greater
confdence in their understanding of
hypertension and desire to play key
roles in its prevention and control
within their communities. Future
training for CHWs should consider
providing a broader package of
information beyond hypertension to
cover more NCDs.
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Pre-implantation Genetic Testing (PGT) Survey
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Are you will Ing to take this voluntary survey on Pre-Implantation Genetic Testing (PGT) for sickle cell

disease?
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Preimplantation genetic testing
(PGT) is a screening modality used in
conjunction with in-vitro fertilization
(IVF). For parents concerned about
hav i ng a ch i ld w ith sick le cel l
disease (SCD), PGT is an option
to have progeny negative for the SS
phenotype. Parents who already have
a child with sickle cell disease (SCD)
may also consider PGT as an option to
have a sibling who is an HLA subtype
match. Parents’ views of this preconceptive diagnostic screening are
not well known1 and little work has
been done in educating parents about
this process2,3. This study sought
to describe parents’ opinions on
PGT after a clinic-based educational
intervention.

Methods
A five-page educational handbook
was created on PGT for SCD. At
the Children’s National Hospital
(Children’s National) HematologyOncology Clinic, parents of children
with SCD were encouraged to read
this handbook in the waiting room
and ask their provider questions about
the material during their clinic visit.
After this visit, parents were then
asked to complete a 24-question
anonymous survey via REDCap (see
figure 1 below). An IRB waiver of
consent was granted as no personal
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FIGURE: Page one of PGT survey completed by parent participants
health information was collected.
Non-biological parents and other
guardians were excluded. Categorical
data from the survey was analyzed
with the chi-square or Fisher exact
test (p<0.05=signifcant).

Results
B e t w e e n M a y a n d Ju l y 2 019 ,
83 biological parents of children
with SCD were enrolled into the
study. Sixty-seven (81%) of these
parents, including 52 mothers and
15 fathers with a median age of 34
years, completed the questionnaire.
While 53 (79%) indicated that they
had previously heard of bone marrow
transplant for SCD before the date
of the questionnaire, only 16 (24%)
indicated that they had also heard of
PGT for SCD (p<.0001). When asked
about their opinion of informing
the parents of SCD children about
PGT, 45 (67%) stated that “knowing
about PGT was ‘very important’,” 20
(30%) responded PGT education was
“important,” one responded (2%) “a
little important,” and one (2%) “not
important.” The majority (69%) of

parents indicated that education on
this topic should occur “at the very
first hematology clinic visit.” Nine
(13%) responded that they would pay
retail price (~$20,0000) for PGT
and 65 (97%) answered that they
think PGT should be covered by
health insurance. Among parents
who indicated that they might want
to have more children (n=32), 29
(91%) answered that they would be
interested in using PGT if covered
by insurance.

Conclusion
Most parents of children with SCD
seen in the Children’s Nationa l
hematology-oncology clinic do not
know about PGT, but when educated
about this option, they view this
knowledge as important. Routine
follow-up appointments in early
childhood may be an opportune
time for educating patients on
PGT. Though the current cost of
PGT remains a major barrier, this
preconceptive diagnostic screening
method may prove to be a major
inf luence in reducing the number
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of pediatric patients with SCD, and
providers should be sure educate
parents on PGT to help ensure access
to this option.
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The Lancet Commission on Global
Surger y established the goal for
nations to achieve universal access
to safe, afordable surgical and anesthesia care when needed.1 In Eastern
sub-Saharan Africa, over an additional
17 million surgical procedures are
needed annually to prevent morbidity
and mortality.1 The Commission set
out universal targets to achieve the
proposed goals; one of which is for
100% of countries to track surgical
volume and preoperative mortality
rate (POMR).1 The Ethiopian Federal
Ministry of Health’s Health Service
Qua lit y Directorate recognizes
this importance by listing it under
its National Health Care Quality
Strategy.2 This investigation looks to
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\
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ENT
12%

Orthopedics
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Ophthalmology
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08-GYN
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FIGURE 1: Summary of Surgical Backlog Assessed by Specialties Among Six
Ethiopian Public Hospitals
study the details of surgical backlog
among six Ethiopian public hospitals
in the Amhara region.
Standardized surveys were sent
out to the surgical department of
six Ethiopian public hospitals in
the Amhara region: Debre Markos
Referral Hospital, Dessie Referral
Hospital, Debre Birhan Referral
Hospita l, Debre Tabor Genera l
Ho s p it a l , G o n d a r Un i v e r s it y
Comprehensive Specialized Hospital,
and Feleghiwot Referral Hospital.
Among the questions asked was the
total number of patients on the waiting
list for elective surgery under one
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of nine surgical departments; ENT,
General, Neurosurgery, OB-GYN,
O pht h a l molog y, O r t hoped ics,
Pediatrics, Plastics, and Urology. In
addition to the survey, first person
interviews with the chair of various
surgical departments were conducted
at Gondar Hospital.
When looking broadly at all centers, there were a total of 4207 cases
of backlog. According to Figure 1,
the departments with the greatest
backlog were General with 2044
cases accounting for 49% of the
Continued on p. 36
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Continued from p. 35
total, Orthopedics with 652 cases at
15%, and ENT with 496 cases at 12%.
Each hospital has its own profle of
needs, ref lecting the complexities
faced by regional health bureaus. As
a case sample, in depth analysis was
conducted at Gondar Hospital which
recorded 1,762 cases. The pattern of
backlog varied compared to that of
the overall fndings, with 45% of cases
within General Surgery, while 30%
were within ENT. Figure 2 highlights
how the diagnoses associated with
the highest backlog are tonsillitis at
44%, and goiters at 30% of all hospital
surgical cases. First person interviews
conducted among the various surgical
department heads highlighted that
the main causes of backlog are due to
either space or equipment limitations;
the quality and quantity of human
resources are adequate.
One limitation of the study is
the var ying methodologies used
to monitor backlogs. For example,
Ophthalmology at Gondar’s Hospital
maintains its own records in hard
copy, while records from other departments are maintained on a centralized
electronic system. Another limitation
is recognizing that low backlog does
not necessarily indicate low burden.
At Gondar Hospital, there is lack of
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Figure 2: Summary of Surgical Backlog Assessed by
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FIGURE 2: Summary of Surgical Backlog Assessed by Diagnoses at Gondar Hospital
OB-GYN backlog burden because of
public health campaigns to champion
maternal and child health outcomes.
Simultaneously, there is also minimal
backlog within Neurosurgery because
cases that the hospital is unable
to support are referred elsewhere,
highlighting that the burden may be
shifted to another site. In conclusion,
assessing the tremendous baseline
of surgical backlog is the first step
to tracking the hospitals’ surgical
volume and POMR. Individual hospitals must be investigated in depth to
assess their specifc needs. It is recommended that future steps be taken to

minimize the backlog and determine
evidence based methods to prevent
future occurrences. The success and
limitations of these future steps can
be used to inform strategies at other
Ethiopian public hospitals.
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Utilizing Role-Play in Teaching Medical Spanish
Khashayar
Mozaffari, MSII

Exam category

Pre-course mean
± SEM(¾)

Multiple choice

95.24 ± 2.32

Oral translation:
80.00 ± 5.85
English to
Spanish
Oral translation:
81.43 ± 3.88
Spanish to
English
SEM: Standard error of the mean
WSR: Wilcoxon signed-rank test
• indicates statistical significance

ADVISORS:
Benjamin Blatt,
MD,1,2 Victor A
Valdivia Ruiz, PhD3
The George
Washington University (GW) School of
Medicine and Health Sciences
2
The GW Medical Faculty Associates
3
GW Department of Romance, German, and
Slavic Languages and Literatures
1

There are 58.9 million Hispanics
in the United States.1 This number
makes up 18.1% of the nation’s population and is expected to increase
to 24.5% by 2050.1 Nearly 40% of
Hispanic patients are categorized as
having limited profciency in English.2
With the aim of training future
health care providers with adequate
Spanish profciency, many health sciences institutions have implemented
medical Spanish courses. Although
interactive courses have shown efcacy in teaching field-related terminology, there are still signifcant
barriers to implementing a medical
Spanish curriculum.2,3 According to a
national survey of medical schools in
the United States, lack of time is the
most frequently reported obstacle.2
Role-play may ofer a time-efcient
manner for students to learn Spanish
and reduce this barrier. In our study,
we investigated the potential beneft
of role-play in a medical Spanish
course.

Methods:
Upon receiving approva l by the
Instit utiona l Rev iew Boa rd, 19
incoming second-year medical students were recruited to participate.
Based on their performances on a
placement test composed of multiple

Pre-course
range(%)

Post-course
range(%)

86.1 1-100.00

Post-course
mean ± SEM
(%)
99.21 ± 0.79

WSRp-value

94.44-100.00

0.10

60.00-100.00

93.57 ± 3.22

80.00-100 .00

0.08

70.00-95 .00

95.71 ± 2.76

80.00-100.00

0.03*

TABLE: Comparison of pre-course and post-course examination scores in the
intermediate group
ex a m i n ation scores, t here wa s
improvement of scores in all categories (Table). In particular, we found
statistically signifcant improvement
in oral translation of phrases from
Spanish to English (p-value= 0.03).

a Spanish-spea king
patient, an English[W]e found statistically signifcant improvespeaking provider, and
an interpreter to pracment in oral translation of phrases from
tice scenarios that one
may encounter when
Spanish to English (p-value= 0.03).
providing health care.
The scena rios conConclusions:
sisted of patients presenting to the
We investigated utilizing role-play
emergency department, outpatient
as the central teaching method in a
clinic, and inpatient hospital setting.
medical Spanish course. The cohort
At the end of the course, students
demonstrated statistically signifcant
took a post-course examination
improvement in oral translation of
to determine if there had been an
phrases from Spanish to English,
improvement in their Spanish lanindicating an improvement in Spanish
guage profciency. Due to the nonprofciency. More importantly, this
normal distribution of scores, statiswas accomplished through a minimal
tical analysis was performed using
time requirement of one hour per
Wilcoxon signed-rank test. Statistical
week, as limited time poses a barrier
signifcance was determined using a
to implementing a medical Spanish
p-value < 0.05.
curriculum. Such fndings highlight
Results:
the beneft of this teaching methodSeven students, who were all members
ology and call for further evaluation
of the intermediate group, completed
in a larger sample size.
the course. Class attendance among
this group was 77.40%. When comparing pre-course to post-course
Continued on p. 38
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Adaptive sports are broadly defned
as conventional sports that have been
modifed to meet the needs of people
with physical and/or intellectual disability. Recently, an emerging body
of literature dedicated to individuals
with disability has demonstrated
that participation in adaptive sports
is associated with certain benefits,
including chronic disease prevention,
increased muscle strength, improved
sense of self esteem and self image,
as well as better social integration.1,2
Additional studies have even suggested participation in adaptive
sports makes a diference in attaining
employment.3 Among those with disability, U.S. Military veterans are a
particular group of interest in part due
to the infux of veterans living with
disability in the post-9/11 era. Data
from the 2014 Census demonstrates
that there are at least 3.8 million
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P-value
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0.1464
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<0.0001 •
<0.000 1•
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0.0784
<0.0001 •

VA Association
VA Partner
VA Partner Type

0.0234
0.0174

FIGURE 1:

veterans living with service-related
disability. 4 Given the documented
physical, psychosocial, and socioeconomic benefts associated with adaptive sports, it is critical that we continue investigating means to increase
participation rates among veterans
with disability. Known barriers to
participation include difcult access
to transportation, limited information about programs and their oferings, individual cost, and program
funding.5 Many of these obstacles
are cost-related. Despite the large
number of adaptive sports programs
in the United States, little is known
about the organizations that provide
adaptive services. To our knowledge,
there are no studies that specifcally
focus on the organizational factors
U.S. Military veterans fnd desirable
when considering getting involved in
adaptive sports.

Objective:
The aim of this study was to capture
the factors within adaptive sports
organizations and their surrounding
communities that impact U.S. military veteran participation in adaptive
sport activities.

Design, Setting, and
Participants:
This study was approved by the
Institutional Review Board at the
George Washington Universit y,
as well as the Milwaukee, VA. A
9-question survey was created by
the investigators of the study and
distributed to 121 programs across the
United States (Figure 1). Participating
organizations were identifed if they
were advertised in the resources section under “Sports and Recreational
Orga n i zations” on w w w.spor tsabilities.com/[STATENAME].
Additionally, surveys were sent to
programs known to the authors, but
not listed on the Sports Abilities
website. Chi-Square Tests were used
to explore possible factors, including
program status, the total number of
participants and veteran participants,
participant age, sports ofered, seasonality, and relationship with the
VA, potentially affecting veteran
participation in adaptive sports
programs. Due to the high number
of tests performed, to control the
family-wise error, p-values were not
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considered to be signifcant unless
they were smaller than 0.005.

Intervention:
Prospective, cross-sectional ninequestion survey about the program’s
demographics.

Main Outcomes and
Measures:
Demographic data.

similar aged individuals is important
to veterans when choosing adaptive
sports programs. No sport was signifcantly associated with percent of
veteran participation, illustrating that
factors beyond the specifc activities
ofered by a program impact veteran
participation rates.
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Results:
In total, 85 programs responded to
our survey, yielding a response rate
of 70%. Age of participants within
an organization was significantly
associated with percentage of veteran
participation. Contact level, seasonality, and VA partnership were not
associated with percentage of veteran
participation (Figure 2). No individual
sport was signifcantly associated with
percentage of veteran participation,
though fy-fshing approached statistical signifcance (p = 0.007)

Conclusions and
Relevance:
Older age among participants within
an adaptive sports organization was
associated with a higher percent of
veteran participation, suggesting
that the camaraderie developed with
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Cardiac rehabilitation (CR) programs
employ a multipronged approach of
exercise and lifestyle modifcations
to reduce cardiometabolic risk factors, improve physical function, and
improve quality of life for patients
with a wide range of cardiac pathologies. Prior research has demonstrated
that cardiac rehabilitation can beneft both men and women’s exercise
capacity after sustaining a myocardial
infarction (MI).1 However, women
are consistently underrepresented
in CR and are often referred to CR
only when they present with greater
cardiovascular risk than men.2
The purpose of this systematic
review is to investigate the diferences
in functional capacity, measured
by metabolic equivalents (METs),
between men and women after an
intensive cardiac rehabilitation program for MI recovery. While several
systematic reviews have compared
compliance and referral rates between
men and women to cardiac rehabilitation, none have assessed potential
diferences in functional capacity or
other health outcomes.
Search strategies were developed
using MeSH heading and free-text
terms for four databases: PubMed,
S C OP US , a nd C I NA H L , a nd
Cochrane. Article duplicates were
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FIGURE: Metabolic Equivalents (kcal/kg/hour) by Gender
eliminated and the remaining titles
and abstracts were screened. Papers
were considered relevant if they
compared outcomes in cardiac rehabilitation between men and women,
if they were published in English and
if they were classifed as a randomized or observational study. Data was
collected using a standardized form,
recording study type, the study population, what, if any, cardiac rehabilitation was implemented, the time points
at which the outcomes were measured
and the functional exercise outcome
regarding MET improvements.
A total of 9,986 records were identifed from the preliminary search and
15 studies were ultimately included in
the review. No eligible randomized
controlled trial was identifed. All 15
studies utilized in this review reported
that both men and women benefit
from cardiac rehabilitation, as demonstrated by a statistically signifcant
increase in peak METs in both gender
groups after CR. Improvements in
absolute METs during CR, reported

by 13 studies, ranged from 0.9 to 2.6
for women and 0.8 to 3.8 for men.
Percent improvements in METs from
baseline, reported by four studies,
ranged from 6.1% to 35% in women
and 10.6% to 45% in men. Six studies
showed MET improvement with CR
to be greater than that of women
by a statistically signifcant margin.
However, only one study showed the
reverse, a greater MET improvement
with CR for women than men, to
be true in a statistically signifcant
fashion. The remaining eight studies
showed no statistically signifcant differences between men and women in
regards to change in METs with CR.
Although all 15 studies demonstrated that both men and women
benefit from CR in terms of MET
improvements, the majority of studies
had more males than females as
study subjects and thus in their CR
programs. Given the proportional
underrepresentation of women in
these studies, however, it is difcult
to speculate the existence of a true
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difference in MET improvements
and also the reasons for a such a difference. Further research is needed
to solidify these diferences in peak
MET improvement between the
genders, if they are true representations of the study population, with
increased numbers of female study
subjects included.
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Introduction/Rationale
Cystic Fibrosis (CF) is an autosomal
recessive disease affecting more
than 30,000 people in the United
States. Pulmonar y exacerbations
(PEx) are the most important cause
of morbidity and ultimately mortality in patients with CF.1 Despite
many studies of bacterial taxonomy
and microbial diversity in the CF
airway, the microbiologic cause of
PEx remains unknown. While early
unbiased whole genome sequencing
studies have yielded greater insights
into species and strain specificity, 2

CLINICAL RESEARCH

·----~
·---
·------
·----·
·------·•

...,A'l.c>'$

___

_

FIGURE: (A) Differential abundance of bacterial metabolic pathways between
exacerbation onset samples (left) and end of antibiotic treatment samples (right) (B)
Differential abundance of bacterial metabolic pathways between exacerbation onset (left)
and follow-up samples (right) (C) Differential abundance of bacterial metabolic pathways
between end of antibiotic treatment samples (right) and follow-up samples (left)
the role of bacterial functional pathways in CF PEx is understudied. We
hypothesized that bacterial metabolic
pathways would be associated with
clinical state (PEx, end of antibiotic
treatment, and follow-up).

Methods
Twenty seven persons less than 18
years of age with cystic fbrosis, who
were admitted to the hospital for a
PEx, were recruited to participate
in this prospective observational

study. Sputum or orophar yngeal
swabs were collected at hospital
admission, at the end of the antibiotic treatment course, and again at
the next follow up clinic appointment within three months. Bacterial
DNA was extracted using QIAamp
DNA Microbiome kit (Qiagen) and
shotgun DNA sequencing was performed using NextSeq (Illumina).
Continued on p. 42
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Continued from p. 41
HUMAnN2 was used to evaluate
bacterial pathway abundance and
DESeq2 was then used to evaluate the
diferential abundance of generalized
bacterial metabolic pathways based
on clinical state.

Results
Several pathways related to virulence,
pathogenicity and bacterial metabolites were upregulated in follow-up
samples when compared to PEx onset
or end of antibiotic treatment samples. Interestingly, we found several
long chain fatty acid (LCFA) biosynthesis pathways that were upregulated
in follow-up samples (Figure). These
include gondoate (log2 fold change
1.59, p=0.012), oleate (log2 fold change
1.746, p=0.048), palmitoleate (log2
fold change 1.766, p=0.043), and pathways of fatty acid elongation (log2
fold change 2.06, p=0.012). While
short chain fatty acids (SCFAs) have
been shown to reduce infammation,
LCFA’s have previously been associated with increased lung infammation in asthma, another important
airway disease.
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Conclusions
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While most current research on
LCFAs and the lung pertain to fatty
acids introduced through diet or in
the lab, we hypothesize that LCFAs
produced by lung pathogens in the CF
airway can have a physiologic efect
like gut derived bacterial SCFAs.
Gut derived SCFA’s have been
studied extensively as yielding a
protective effect on inf lammation
leading to protection in infammatory
diseases across multiple organ systems
and to be associated with infammatory illnesses.3 In contrast, LCFAs
introduced through diet and in the lab
have been shown to induce bronchial
cell proliferation, airway remodeling
and airway smooth muscle contraction – all important factors in lung
infammation and exacerbation.4,5
As we found long chain fatty pathways to be upregulated in follow-up
samples, LCFAs produced by bacteria
in the CF lung should be studied further for potential impact on future
PEx. This may help us further characterize the role of bacteria produced
LCFA’s on the transition between
clinical states.
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Do Initial Tidal Volumes Matter in the
Setting of the Emergency Department?
Arjun Panda,
MSIII
Unadjusted
P

EDVT
adjusted
OR (95% CI)
or adjusted
ln[β (SE)]

Adjusted
P

1 19 (0 97 - 1 47)

0 1033

0 99 (0 75 –
1 32)

0 9863

Vent Days

0 0332 (0 0375)

0 3752

0 0760
(0 0408)

0 0627

ICU Days

-0 0072 (0 0393)

0 8539

0 0468
(0 0442)

0 2901

Hospital Days

-0 0224 (0 0420)

0 5942

0 0331
(0 0485)

0 4951
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Learning Objectives
Mechanical ventilation is a lifesaving
therapy however, it may pose a threat
to patients if set inappropriately. Prior
studies suggest that tidal volumes
(TVs) based on ideal body weight
(IBW) are associated with improved
outcomes for intubated patients. We
sought to determine whether TV settings based on IBW correlated with
clinically relevant patient outcomes
for patients intubated in the emergency department (ED).

Methods
We performed a retrospective review
of electronic medical records from
January 2016 to December 2018 for
intubated patients in the ED. We collected data including: patient demographics, height, weight, lab values,
and ventilator settings in the ED.
We calculated IBW for all patients to
determine the tidal volume per kilogram given in the ED. We stratifed
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Outcome

EDVT unadjusted
OR (95% CI) or
unadjusted ln[β
(SE)]

Death

TABLE: The Effect of Tidal Volume Settings in the ED on Patient Outcomes

the TVs based on low (<8cc/kg ),
intermediate (8-10cc/kg), and high
(>10cc/kg). We assessed the impact
of TV on the following outcomes:
ventilator days, intensive care unit
(ICU) days, hospital days, and death.
Multivariable logistic and general
linear models were assessed adjusting
for baseline demographics, clinical
variables, and illness severity to better
elucidate the independent efect of
tidal volume on outcomes of interest.
Length of stay (LOS) outcomes were
natural logarithm (ln) transformed to
meet the assumptions of normality
and linear regression.

Results
Two hundred seventeen patients had
full data record for analysis. Average
age was 59.7 ± 15.4 years old (mean
± standard deviation). 90 (41.5%)

patients were female and 127 (58.5%)
were male. Median SOFA score was 8
with interquartile range 6–11. Median
LOS for days on ventilator, days in
ICU, and days in hospital were 3, 5,
and 8, respectively. 64 (29.5%) patients
experienced mortality. Adjusted
analysis detected no independently
signifcant relationship between any
of the IBW ED tidal volume per kg
and mortality, ICU days, or hospital
days (Table).

Conclusions
This data suggests that the TV size
did not significantly affect patient
outcomes. There was no association
between low, intermediate or high
TV and mortality, ventilator days or
hospital days.
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Factors Associated with Emergency Department
Length of Stay in Patients with Acute Gout
Murwarid
Rahimi, MSII

< 4.3 hours in ED
(n = 265)

> 4.3 hours in ED
(n = 90)

Age < 65

185/265 (69 8%)

51/90 (56 7%)

Male gender

213/264 (80 7%)

75/90 (83 3%)

Diabetes

68/228 (29 8%)

29/76 (38 2%)

Hyperlipidemia

132/228 (57 9%)

53/76 (69 7%)

History of gout

160/228 (70 2%)

54/76 (71 1%)

Hypertension*

162/228 (71 1%)

65/76 (85 5%)

Coronary artery disease

49/228 (21 5%)

21/76 (27 6%)

Heart failure*

32/228 (14 0%)

26/76 (34 2%)

Chronic kidney disease

44/228 (19 3%)

21/76 (27 6%)

Cerebrovascular disease

19/228 (8 3%)

4/76 (5 3%)

Other infammatory arthritis

10/228 (4 4%)

3/76 (4 0%)

Oligo/polyarticular gout

33/265 (12 4%)

13/90 (14 4%)

Arthrocentesis*

21/265 (7 9%)

51/90 (56 7%)

ED Severity Score*
Score 2 and 3
Score 4 and 5

117/265 (44 1%)
148/265 (55 8%)

67/90 (74 4%)
23/90 (25 6%)

Type of Hospital*
Academic center
Community center

204/265 (77%)
61/265 (23%)

82/90 (91 1%)
8/90 (8 9%)

Time of Day
Time of day (12 am – 8 am)
Time of day (8 am – noon)
Time of day (noon – midnight)

52/265 (19 6%)
124/265 (46 8%)
89/265 (33 6%)

20/90 (22 2%)
51/90 (56 7%)
19/90 (21 1%)

Time of Year
January to March
April to June
July to September
October to December

43/265 (16 2%)
94/265 (35 5%)
78/265 (29 4%)
50/265 (18 9%)

21/90 (23 3%)
28/90 (31 1%)
19/90 (21 1%)
22/90 (24 2%)

Weekend presentation

94/265 (35 5%)

24/90 (26 7%)
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Emergency department (ED) visits
for acute gout have increased by
approximately 20% between 2006
and 2014.1 Reducing the ED length of
stay (LOS) can help reduce cost of care
for gout patients and ED crowding.2
We assessed the ED LOS and factors
associated with it in patients with acute
gout. A retrospective analysis was
conducted and included the frst ED
visit of adult patients with acute gout
who presented to the 3 EDs afliated
with Lifespan Health Systems, the
largest healthcare provider in Rhode
Island. The ED LOS was the time
spent by patient in the ED until they
were discharged. Patients presenting
to the ED and subsequently admitted
to the hospital were excluded given
the diferential efect of system factors in these patients. Both patient
factors, such as clinical presentation
of gout, as well as systems factors were
assessed. Univariate and multivariable analysis were completed. The
univariate analysis demonstrated that
patient factors such as older age (>65
years), comorbidities (hypertension,
congestive heart failure), and worse
ED severity score were associated
with being in the upper quartile of ED
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Patient factors

Comorbidities

Clinical presentation of gout

Systems factors

*Represents statistically signifcant results (p <0 05)

TABLE: Factors Associatedwith Increased ED Length of Stay in Gout Patients
LOS in addition to being treated in
an academic setting. A multivariable
analysis showed that persons of age

greater than 65 years and a worse acuity
score continued to be associated with
longer ED LOS. Overall, the study
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demonstrated patients with acute gout
spent a longer time in the ED than the
national median of 120-150 minutes.
Older age and a higher acuity score in
addition to procedural delays led to
longer length of stay in the ED.
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Learning Objectives
Given the high mortality rate in
patients with cardiac arrest, previous
research has sought to determine
factors that distinguish patients
who are likely to have return of
spontaneous circulation (ROSC)
from those in whom continued
resuscitation is futile.1 Prior research
utilizing multiple imaging modalities
such as Ultrasound and CT scan
has suggested an association of the
presence of hepatic venous air with
mortality.2 As point of care ultrasound
(POCUS) is already becoming more
frequently used in the context of
resuscitation, we sought to evaluate
if the presence of any hepatic air,
parenchymal or venous, on POCUS
had a similar mortality association.

Methods
We completed a retrospective review
of patients at George Washington
University Hospital, who experienced
non-traumatic cardiac arrest and had
POCUS with adequate views of the
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hepatic parenchyma. The majority
of these images were sub-xiphoid
eva luations of ca rd iac activ it y,
with incidental capture of the liver.
Archived ultrasound images were
independently reviewed to determine
the presence of hepatic parenchymal
and/or hepatic venous air. Electronic
medical records were then reviewed to
collect other clinical data, including
admission rate to ICU and overall
hospital mortality.

Results

CONCLUSION
Our study demonstrated that the
incidence of post-arrest hepatic air
on POCUS was common, although
the presence of air in parenchyma
alone did not signifcantly distinguish
patients with respect to mortality.
Hepatic venous air, however, may be
of prognostic value as it could act as an
indicator of mortality. Further studies

Our study demonstrated that the incidence of

From Jan. 1, 2017
post-arrest hepatic air on POCUS was common,
th roug h June 16,
2019, 87 patients
although the presence of air in parenchyma
met inclusion
criteria, including 6
alone did not signifcantly distinguish patients
In-hospital cardiac
arrests (ICHA) and
with respect to mortality.
81 out of hospital
cardiac arrest
are necessary to better describe this
(OCHA) Ultimately, 68 (78.2%) died
phenomenon.
and 19 (21.8%) survived. Of those
who died, 40 (58.8%) had hepatic air,
REFERENCES:
while 28 (41.2%) had none. Of those
1. Lien WC, Chang WT, Huang SP, et al.
who died with hepatic air, 38 (95%)
Hepatic portal venous gas associated with
demonstrated parenchymal air, while
poor outcome in out-of-hospital cardiac
27 (67.5%) demonstrated venous air. Of
arrest patients. Resuscitation. 2004
the survivors, nine (47.4%) had hepatic
March;60(3):303-7.
air, while 10 (52.6%) had none. Only a
2. Reuter H, Ba nga rd C , G erha rdt F,
single survivor demonstrated hepatic
Rosenkranz S, Erdmann E. Extensive
venous air (11%). While the diference
hepatic portal venous gas and gastric
emphysema after successful resuscitation.
in mortality with respect to presence
Resuscitation. 2011 Feb;82(2):238-9.
of undifferentiated hepatic air was
not signifcant (p=0.37), there was a
signifcant diference with respect to
the presence of venous air (p=0.0046).

45

The Utility of Bandemia in Prognostication and
Prediction of Mortality in Sepsis
Amir Rashed,
MSIV

Methods

We performed a retrospective chart
review of patients admitted to our
Nivi Prasanna, MD,1
tertiary care ICU for sepsis or septic
Benjamin DelPrete,
shock from the ED. Patients were
DO,1 Andres Garza
excluded if their bandemia was due
MD1
to etiologies other than sepsis. We
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Organ Failure Assessment (SOFA)
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scores, vasopressor use, and the
The George Washington University School of
clinical course of 134 patients included
Medicine and Health Sciences
in our study at 0 and 72 hours after
admission. Worsening clinical course
Sepsis remains a leading cause of death
was defined as increasing SOFA
in the United States despite advancescores or the initiation and conments in early recognition and inititinuation of vasopressor support
ating prompt treatment.1,2 Bandemia,
at 72 hours. Patients were analyzed
based on SOFA trends (SG=SOFA
defined as a band count >10%, is
group) and vasopressor
trends (VG=vasopressor
This data suggests that the clearance of
g r o u p). T h e y w e r e
d istr ibuted a mong
bandemia can be used as a marker of clinical
groups 1-4 SG based on
resolving, steady-state
improvement in sepsis. It also shows that
or worsen i ng SOFA
scores, and groups 1–4
worsening bandemia is predictive of deteVG based on improving,
steady-state or worsening vasopressor
riorating clinical status and higher mortality.
requirement.
CO-AUTHORS:

highly indicative of underlying infection and is increasingly being used
in the emergency department (ED)
and the intensive care unit (ICU) for
identification of sepsis.3 Bandemia
has been linked to worse outcomes,
but its trend in the intensive care unit
(ICU) is not well studied. 4,5 In this
retrospective study, we assessed the
severity of bandemia at 0 and 72 hours
among patients admitted to the ICU
for sepsis or septic shock to evaluate if
there was a direct correlation between
increasing bandemia and clinical deterioration among these patients.
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Results
Among the 134 patients included
for a na lysis, the average SOFA
score on admission was 6. Based on
SOFA scores and vasopressor trends
between hour 0 and hour 72, there
was a statistically signifcant improvement in bandemia for patients in
Group 1 (Range -10.3 ± 15.3, Mean
-6) with resolving sepsis (P<0.0001
SG, P<0.0001 VG) and a statistically
significant worsening in bandemia
(Range 10.1 ± 6.4, Mean 7) for patients
in Group 3 with worsening sepsis
(P=0.0001 SG, P=0.0007 VG).

Conclusions
This data suggests that the clearance
of bandemia can be used as a marker
of clinical improvement in sepsis. It
also shows that worsening bandemia
is predictive of deteriorating clinical
status and higher mortality. The presence of bandemia and its trend in the
ICU can, therefore, be used to guide
the safe de-escalation of antibiotic
therapy in the ICU, and potentially
decrease the total duration of antibiotic use.
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Septic shock is a common condition
characterized by host immunodysregulation secondary to an infectious
etiology leading to hypotension and
lactic acidosis secondary to organ
breakdown.1 Recent investigations suggest that this dysregulation is biphasic,
being initially a hyperimmune reaction
resulting in systematic infammation
followed by long term immunosuppression and associated sequalae.1
Given that the major player in sepsis
and septic shock is not the ofending
pathogen but rather the response of the
host immune system to that pathogen,
it is crucial to develop a more robust
understanding of the immune system’s
essential role in this pathology and the
role of conditions that modulate the
immune system in the pathogenesis of
sepsis, especially in vulnerable populations.1 Classically, and more commonly
in adults, sepsis presents with decreased
systemic vascular resistance (SVR) and
warm extremities due to systematic
endothelial disruption (warm shock),
while pediatric cases tend to exhibit
increased SVR and cold extremities
(cold shock). 2,3 However, in pediatric populations with still maturing
immune systems, the phenotype of
septic shock is less understood. The
purpose of this study was to evaluate
diferent phenotypes of septic shock in
a selected pediatric population.
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FIGURE: Beats per minute (BPM) and mean arterial pressure (MAP) in septic patients by age
To do this, we created a casecontrol study in which we followed the
hospital courses of sixteen pediatric
patients hospitalized at the Children’s
National Hospital between 02/2018
and 07/2019, eight of whom were
admitted for septic shock and eight
of whom were admitted for another
condition to serve as a control. Care
was taken to ensure that the control
group did not include patients with an
infammatory or infectious pathology
or condition or had taken any immunomodulatory medication to avoid any
confounding data. The study patients
were then further subdivided by age
and key metrics, including gender,
history of chronic illness, etiologic
agent as determined by blood cultures,
recurrent antibiotics use, oxygen
saturation, erythrocyte sedimentation rate, C-reactive protein levels,
white blood cell count, temperature,
heart rate, and blood pressure. Due to
the emergent nature of septic shock,
there is an inevitable variation in the
exact time of clinical presentation and
therefore a spread in when specifcally
our data was collected, however all

data included within this study was
collected within 24 hours of the presentation of initial symptoms of SIRS
among children with septic shock.
We observed that patients aged less
than 12 years exhibited a septic shock
phenotype distinct from patients
over the age of 12. Patients with septic
shock above the age of 12 had higher
heart rates compared to control,
while patients younger than 12 did not
significantly from control (Figure).
Furthermore, we found that mean
arterial pressure (MAP) was signifcantly lower in children with septic
shock older than 12 compared to their
younger counterparts (Figure). These
fndings could be due to fundamental
diferences in the physiology of children as compared to adults, such as
the inability of children to modulate
their cardiac contractility in the same
manner as adults.2 This, in turn, is
complicated by the decreased cardiac
function commonly seen in pediatric
septic shock.4 As such, in order to further unravel the fundamental basis of
Continued on p. 48
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Continued from p. 47
these phenotypes, future work will be
focused on the extraction and isolation
of peripheral blood mononuclear cells
from each of the patients present here
with the end goal of examining and
characterizing the immunometabolic
status of each of these patients.5 We
hope that such an approach will help
illuminate the fundamental principles
underlying such observations, which in

turn may prove crucial to developing
novel methodologies for the treatment
of sepsis.

Medicine. 2013;369:840-51.
3.
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Learning Objectives
Refractory shock remains a challenge
with nearly ubiquitous mortality.
Novel therapies a re needed to
m a i nta i n hemod y n a m ics when
conventional mechanisms, have failed.
Several exploratory therapies display
potential efficacy in the literature,
however it remains unclear which
therapy is superior.1,2 We aim to clarify
the efficacy of the current salvage
therapies: Angiotensin II (ATII) vs
Methylene Blue (MB) vs Vitamin C
with thiamine and hydrocortisone
( Vit C) for refractory shock. We
hypothesize that these therapies will
improve survivability and decrease
the need for other vasopressors in
patients with refractory shock.

48

Methods
This study is a retrospective review of
patients with refractory shock started
on ATII, MB, and/or Vit C in a single
center mixed ICU. We collected baseline demographics, shock etiology,
APACHE II, mortality, etc. The primary outcome was mortality and the
secondary outcome was the change
in standard vasopressor requirements
after initiation of these therapies.
The groups were analyzed based on
whether they received one intervention
alone, or a combination of therapies.

Results
Fifty six patients were included in
the ATII group, 21 patients in the
MB group, and 114 in the Vit C
group (total n= 191). As monotherapy,
for those that received ATII (34)
mortality was seen in 85.3% (29), for
MB (9) mortality was seen in 77.8%
(7), and for Vit C (79) mortality was
seen in 51.9% (41). After adjusting
for APACHE II, those who received
ATII (monotherapy/combination)
had 2.85 times higher odds of mortality than those who did not receive
the drug (CI 1.28 - 6.33, p=0.0103). Vit
C, however, showed 65% lower odds
of mortality when compared to those

who did not receive it (aOR 0.35, CI
0.14 - 0.87, p=0.0231). No statistical
signifcance was seen for MB (aOR
2.80, CI 0.53-14.78, p=0.2254). The
vasopressor requirements decreased
over the frst 24 hours after starting
therapy with these drugs, but ATII
still required higher doses of norepinephrine and vasopressin compared to Vit C (p=0.0011, p=0.0026
respectively).

Conclusion
While these therapies have shown
improvement in hemodynamics, this
study questions the impact on overall
mortality. These results could be due
to the baseline low survivability in
this patient population or due to not
initiating these rescue therapies soon
enough. More prospective studies are
needed to further clarify their potential role in refractory shock.
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Characteristics

University of Pennsylvania

Mohs micrographic surgery (MMS)
is useful for treatment of melanomas
located on specialty sites (head,
neck, hands, feet, genitalia, pretibial
leg), which have an increased risk
of complications after conventional
excision with post-operative margin
assessment (CE-POMA).1 We previously reported local recurrence rates
of 0.34% (2/597 lesions) for melanoma in situ (MIS) after MMS with
melanoma antigen recognized by
T-cells 1 (MART-1) immunostaining
in a cohort of 563 individuals over
a mean follow up of 2.8 years (0.018.68 years). 2 The same treatment
technique for invasive melanoma,
assessed in a larger cohort, yielded
a local recurrence rate of 1.3% (7/556
lesions).3 We now present our 11-year
experience, which includes fve- and
10-year follow up data.
An IRB -approved retrospective cohort study was performed to
evaluate the local recurrence rates
of invasive and in situ melanomas
treated using MMS with MART-1
immunostaining at the University
of Pennsylvania between 2006 and
2017. Data for all patients were prospectively entered in an electronic
database at the time of surgery and
includes patient demographics, tumor
characteristics, anatomic location,
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Female
Male
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Tumor Location (n, %)
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Head/Neck
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ression status n %
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Median
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Tumor Characteristics
Recurrent Prior to Initial Surgery (n, %)
Subclinical Spread (n, %)
Breslow Depth mean (range) (mm)
Mitoses mean (range) (l /mm 2)
UlceratiOIIJ)resent (!I, ~

Tumor Size
Mean Length (mm)
Mean Width (mm

2.1

1.7

Number of Stages (n, %)
Mean (range)
0

2
3
4

5
6
7

TABLE: Patient and Tumor Clinical Characteristics
and previous treatment. Patients
were excluded if there was evidence
of locoregional or distant metastasis
at the time of surgery or clear margin
status was not achieved using frozen
section interpretation alone (for
example, cases for which MART-1
immunostaining was not reliable,
such as desmoplastic melanoma, or
required additional tumor resection
in the operating room). Follow up
information was obtained through

patients’ medical records or via telephone call as previously described.1
The primary outcome was biopsyproven local recurrence, defned as the
presence of a new lesion in the surgical
scar where MMS was performed or
within 2 cm of the original lesion.
Two thousand one hundred thirtyfour primary or locally recurrent invasive and in situ melanomas without
Continued on p. 50
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Local recurrence free survival
clinical evidence of metastasis were
identifed in 1,973 patients. 186 cases of
183 patients were excluded because 98
patients declined to participate when
consent was sought via telephone, 52
patients were without clinic follow up
and unable to be reached, 29 patients
were deceased and without clinic
follow up, and four patients required
additional resection following MMS.
Follow up information was available
for a total of 1,790 patients with 1,948
melanomas (Table).
Six loca l recurrences (0.31%,
6/1948) were identifed. The majority
of lesions (5/6, 83%) that recurred
were in situ and all lesions were 1
cm or larger at the time of surgery.
One-third (2/6) of recurrences were
recurrent at the time of initial MMS.
The average time to recurrence was
1,347 days for MIS and 285 days for
invasive melanoma. Five and ten-year
minimum follow up information
was available for 458 and 33 cases
respectively. The five- and 10-year
Kaplan–Meier local recurrence-free
survival rates were 0.9946 (95% CI
0.9855-0.9980) and 0.9856 (95% CI
0.9490-0.9960) (Figure).
The overa l l loca l recurrence
rate was low (0.31%) and remained
durable at five- and 10-year follow
up, despite the majority of tumors
located on specialty sites, which have
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FIGURE: Local Recurrence-Free Survival Rate

an average local recurrence of ~10%
following CE-POMA.2 All recurrences after MMS were located on
the scalp, cheek, eyelid/conjunctiva,
or foot, highlighting the challenges
of treating specialty site melanomas.
Our data support the use of MMS
with MART-1 immunostaining to
achieve durable local clearance for
specialty site melanomas.
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Since the early 2000s, there has
been more than a 25-fold increase
in the use of the robotic-assisted
r a d i c a l c y s t e c t o m y ( R A RC )
compared to more conventional,
open radica l cystectomy (ORC)
for bladder cancer.1 Proponents of
this minimally invasive approach
favor the decreased perioperative
comorbidities associated with the
modality, which includes decreased
blood loss, recover y ti me, a nd
complication rates.2–4 Despite these
advantages, the use of RARC has
not gained the same popularity in the
setting of higher grade malignancy,
due to concerns of atypical recurrence
from pneumoperitoneum-induced
immunomodulation, tumor cel l
intravasation and port-site trauma.5
Recent randomized control trials,
notably the R AZOR study, have
d eter m i ne d no d i f f er ence s i n
oncologic or mortality outcomes
compared to the open approach
in bladder cancer as a whole, but
have not sub-stratified by tumor
aggressiveness.2,3 Given the putative
mechanisms, likelihood of atypical
recurrence would presumably be
especially relevant in higher stage,
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FIGURE: Kaplan Meier for overall survival with median survival statistics for ORC and
RARC
locally advanced or node-positive
disease, where the intrinsic metastatic
potential of tumor cells may be
greater. This study aims to compare
the oncologic efficacy of R ARC
compared to ORC, among patients
with stage pT3-4 or node-positive
bladder cancer.

Methods
A retrospective cohort analysis of
pT3-4N0-3 or pT(any)-4N1-3 patients
who under went R A RC or ORC
from 2010–16 was performed using
the Nationa l Ca ncer Databa se
(NCDB). Baseline demographic and
clinicopathologic variables were
compared between treatment cohorts.
Primary outcome of overall survival
was analyzed by way of Kaplan-Meier
estimation with corresponding LogRank test, followed by multivariable
Cox-Propor tiona l Ha za rds

regression. Secondar y outcomes
including 30-day mortality, 90-day
mor ta l it y, 30 - day read m ission,
positive margin status, receipt of
adjuvant radiation or chemotherapy,
and surgical inpatient length of stay
were analyzed by way of Chi-square,
Fisher’s exact, or Mann-Whitney U
test, followed by multivariable logistic
or transformed linear regression.

Results
There were 9,062 ORC cases and
2,544 RARC cases that met inclusion
criteria. RARC was significantly
associated with superior unadjusted
survival compared to ORC (Figure).
Additionally, RARC was signifcantly
associated with lower proportions
of u n adj u sted 30 - a nd 9 0 - d a y
mortality, positive margin status,
and shorter surgical inpatient stay
Continued on p. 52
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Outcome

Adjusted
Adjusted
p
Hazard Ratio
(95% Cl)
Overall Mortality
5954
1564
0.97
0.3239
(61.5)
(65.7)
/0.92 - 1.03)
Adjusted Odds
Ratiof95% en
30 Day Mortality
285
55
0.78
0.1 113
/3.2)
/2.2)
/0.58 - 1.06)
90 Day Mortality
883
199
0.90
0.2137
(9.9)
r7.9)
/0 .76 - 1.06)
30 Day Unplanned Readmission
222
0.99
0.8618
803
/8 .9)
/8.8)
/0.8 4 - 1.16)
Positive Margin Status
1753
439
1.00
0.9652
(19.8)
(17.7)
/0 .88 - I. 14)
Adjuvant Radiation
333
79
0.97
0.8 169
(3.2)
(3.8)
/0.75 - 1.26)
Adjuvant Chemotherapy
2681
734
0.94
0.2306
(30.7)
/0 .85 - 1.04)
/30. I)
Adjusted
In 18 /SE)!
Surgica l Inpatient Stay (days)
-0.1025
8
7
<0.0001 •
(5 9)
/0.0169)
/6 11)
*=stat1st1cally
s1gmficant, P <0.05; CI=confidence mteIVal;ln=naturalloganthm; p=parameterestimate; SE=standard
error;
Note: Forall comparisons
, referencegroup= ORC

(all respective P<0.05). However,
after adjusting for confounding
covariates (demographic variables,
perioperative chemotherapy, clinical
stage, pathological stage, clinical
node status, and surgical margin
status) multivariable analysis revealed
no difference in mortality hazard
or odds of seconda r y outcomes
with the exception of inpatient stay
(Table). RARC was also signifcantly
associated with higher lymph node
yield (increased incidence of >14
lymph nodes examined relative to
ORC; 55% vs. 40%; P<0.01).

Conclusions
RARC is no less safe than ORC for
patients with locally advanced or
node-positive bladder cancer on the
basis of overall, 30- and 90-day survival
outcomes. Unadjusted mortality and
surgical outcomes in this population
demonstrate advantages to the robotic
modality. Perioperative benefits
including shortened inpatient stay
favor RARC, but further randomized
control studies are necessary to better
elucidate diferences between surgical
approaches in this unique population.

52

Open
(n=9062)

Robotic
(n=2544)

TABLE: Multivariate Analysis for Overall Mortality and Oncologic/Surgical Outcomes
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Background/Objective
Extensive resources are devoted to
discovering novel cancer treatment
modalities. Meanwhile, patient priorities and experiences throughout
their diagnoses and in the palliative
care setting must also be addressed.
Specifcally, among adolescents with
cancer, patients’ defnitions of “living
well” may elucidate treatment preferences, guide care teams and families,
and infuence future behavioral interventions. The objective is to develop
an empirical definition of “living
well” for adolescents with cancer to
enhance shared decision-making.

CLINICAL RESEARCH

Design/Methods
Video recordings were analyzed from
the Next Steps: Respecting Choices
interviews with N=30 adolescents
ages 14-21 years with cancer and their
families, a subsample of N=126 adolescent/family dyads participating in
a randomized clinical trial, FAmily
CEntered (FACE) Advance Care
Planning. Videos were transcribed
verbatim by the frst author who did
not conduct the interviews. Using
Krippendorf ’s inductive semantic
content analysis, two authors created
a codebook from two transcripts
by identifying consistent themes.1
Upon completion, the codebook was
then used to independently code two
additional transcripts to maximize
the likelihood of code saturation.
Coding proceeded of the remaining
28 transcripts. Reconciliation was
resolved by consensus to maximize
reliability. Triangulation increased
validity.

Results

and friends, in which shared experiences are more important than the
experiences themselves; (3) wholeness—emotional, physical, and spiritual health; physical health includes
nutritious eating and sleep hygiene;
(4) living a productive life, engaging
in meaningful activities, and living for
more than your own interests.

Conclusions
By determining what “living well”
means for adolescents with cancer,
care teams and families can more
easily understand patients’ priorities.
A firm grasp on patients’ definitions of “living well” could relieve
signifcant burden from families and
increase families’ willingness to honor
adolescent treatment preferences.
Findings may guide future psychosocial interventions.
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“Living well” had four domains: (1)
exercising autonomy over one’s total
personhood; (2) participating in
meaningful relationships with family
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Proximal humer us fractures are
com mon or t hopaed ic i nj u r ies,
constituting approx imately f ive
percent of all fractures in some
studies.1 These fractures exhibit a
bimodal distribution; younger males
sustain these injuries in higher energy
mechanisms, while older females
sustain these fractures with low
energy falls.1
Similar research has been done on
clinical outcome measures following
prox ima l humer us fract ures by
Slobogean et al., 2 but their study
had several notable differences.
The cohort was smaller, limited to
individuals over the age of 55, and
included patients who underwent
either operative or non-operative
management.
Spross et a l. conducted a
retrospective review of 269 patients
with surgically treated proximal
humerus fractures and found older
age to be a risk factor for worse
clinical outcome scores in these
patients. 3 Unlike this study, the
pres ent i nvest i g at ion a ss ess es
patient reported outcomes using
the American Shoulder and Elbow
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TABLE 1: TBaseline patient demographics
Society Survey (ASES)4 and objective
range of motion measurements in
patients who underwent surgery for
proximal humerus fractures

Methods
All proximal humerus fractures from
September 2011 to February 2016
treated at one institution by a single
surgeon were reviewed under IRB
#121615. Patients were contacted
by phone or at a clinic follow up
appointment to complete a validated
clinical outcomes survey (ASES),
which assesses difficult y with a
number of routine tasks involving
the use of the afected shoulder. If
patients had less than one year of
clinical follow up they were asked
to return to the office for range of
motion evaluation.

Results
Of the 127 patients with qualifying
injuries, 57 had greater than one year
follow up and had completed the
ASES survey. Sixteen patients were
excluded because their index surgery
was for a revision or non-union, or
sufficient documentation was not
available for analysis, leaving 41
patients for evaluation in this study.

Patient characteristics are shown in
Table 1. The impacts of age, body mass
index (BMI), and range of motion
(initial and final) on ASES were
examined in a univariate comparison
using Pearson correlations (r), all of
which were found not to be signifcant
in predicting outcome (ASES) score
(p>0.05 for all) (Table 2).

Discussion
Our data suggest that older patients
are no more likely to fare worse than
younger patients at least one year after
surgery. While early range of motion
is conventionally thought of as crucial
to help avoid stiffness, we did not
fnd that difculty with early passive
range of motion was associated with
unsatisfactory clinical outcomes.
That is, even if patients lose range
of motion in their injured shoulder,
this does not signifcantly afect their
quality of life.
There are several limitations to
this study. This is a retrospective
study, and as such cannot determine
the temporal association or causality
of our outcomes of interest. Other
pitfalls specifc to our outcomes of
interest are inconsistency in range of
motion measurements and diferences
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in patient response rates that also are
associated with outcomes of interest.

n=41

Conclusion

ASES score
Age, years

Brvrr

2. Slobogean GP, Noonan VK, Famuyide A,

r

p-va!ue

0_87
0_28
0_72
0_90
0_78
0_68
dev1at1on;

TABLE 2: Univariate association between predictors and postoperative ASES score
O’Brien PJ. (2011). Does objective shoulder
impairment explain patient-reported
functional outcome? A study of proximal
humerus fractures. Journal of Shoulder and
Elbow Surgery. 20(2), 267–272. https://doi.
org/10.1016/j.jse.2010.06.005
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Counseling patients on their functional
prognosis following a traumatic injury
is challenging. While existing evidence
suggests that older patients are likely to
have worse outcomes, our study suggests
that it is not clear that older patients are
at risk of worse self-reported outcomes
than younger patients one year after
surgical treatment for fractures of the
proximal humerus.
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During the past decades, framebased stereotactic radiosurgery, and
Gamma Knife® in particular, has
demonstrated its efcacy and safety
as therapy for Trigeminal Neuralgia
(TN).1 However, few studies exist
using non-frame-based radiosurgery
devices such as CyberKnife (CK),
especially those that report long-term

SURGERY AND ANESTHESIA

follow-up. Our primary objective in
this study is to evaluate the long-term
efectiveness of CK stereotactic radiosurgery on TN pain response.
From 2010 to 2019, 38 patients
were treated for symptomatic trigeminal neuralgia at Virginia Hospital
Center: 68.4% patients were female,
mean age was 72.3 years-old (range,
30 – 93). We performed a retrospective chart-review of these patients in
order to collate predefned variables,
followed by a prospectively collected
follow-up phone survey to collect
most recent health data. CK outcome was measured using the Barrow
Neurological Institute (BNI) scores
for pain and hypoesthesia, which was
statistically evaluated by univariate
and multivariate analyses. We considered a successful CK treatment
as a decrease in BNI pain score from
pre-treatment to follow-up.

CK treatment was initially successful in 87.5% of patients, with
time to max pain relief ranging from
three weeks to 36 weeks (mean, 10.5
weeks). Continued success at most
recent follow-up was reported in
81.3% of patients (mean follow-up,
37.1 months). The median pre-treatment BNI pain score was V and the
median BNI pain score at most recent
follow-up was IIIa, indicating an
improved quality of life. Trigeminal
pain recurred in 18.8% of patients
(range, 1.3 – 2.0 years). New-onset
bothersome trigeminal hypoesthesia
(defned as BNI hypoesthesia=II/III)
was reported in 68.6% of patients.
Increased CK success was found to
correlate with increased BNI hypoesthesia scores (p=.001) as well as
with increased side effects such as
Continued on p. 56
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Continued from p. 55
dysphagia and paresthesia. (p=.003).
Additionally, increased CK success was found to correlate with an
idiopathic pathogenesis of TN pain
in comparison to TN pain derived
from stroke/tumor/surgery (p=.034).
Interestingly, CK success did not
correlate with typical nor atypical TN
classifcation.
Our results demonstrate that CK
stereotactic radiosurgery is an efective long-term therapy for treating
TN. However, patients should be
aware that such symptoms as hypoesthesia, paresthesia, and dysphagia
can occur that correlate with an
effective treatment. Furthermore,
TN pathogeneses should be taken
into account to be used as a possible
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FIGURE: Bar graph of BNI scores
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Stereotactic radiosurgery for trigeminal
neuralgia: A systematic review. Journal of
Neurosurgery. 2019;130(3):733-757.
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The primary treatment of adductor
spasmodic dysphonia is repeated
injections of Botulinum toxin type
A (Botox) into the thyroarytenoid
muscles.1 Dosing can be performed
into either one or both thyroarytenoid
muscles.2 The objective of this study
is to evaluate the treatment efect and
side efect profle across a large number
of injections. A study with the same
objective was performed previously
in 2002 on 45 patients.2 This current
study is a retrospective study of all
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Unilateral

Bilateral

Chi-Squared

Optimal Effect

47%

55%

p= 0 000

Optimal Side Effect

77%

73%

p= 0 023

Optimal Effect/Side Effects

33%

36%

p= 0 0228

FIGURE: Chi-Square Analysis of Those Injections Resulting in an Optimal Effect of three
Months or Greater and an Optimal Side Effect Duration Less Than or Equal to two Weeks

patients with adductor spasmodic
dysphonia with or without tremor
treated by the senior laryngologist at
The George Washington University.
In the current study, 272 patients (214
females and 58 males) were included
in the analysis. Duration of effect
and side efects (vocal weakness and
liquid dysphagia) after each injection
were recorded into a database. This
data was analyzed using Chi-square
analysis. A total of 4023 injections
(2708 bilateral and 1315 unilateral)

w er e e v a l u ate d i n t h i s st ud y.
Optimal effect duration ( greater
than or equal to three months) was
more commonly seen in the bilateral
injection patients (55%) compared
to the unilateral injection patients
(47%) with a p=0.0001. Optimal side
efect duration (less than or equal to 2
weeks) was also better for the bilateral
injection patients (73%) compared
to the unilateral injection patients
(77%) with a p=0.023. Having both
optimal efect and side efect in the
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same injection was more commonly
seen in the bilaterally injected patients
(36%) compared to the unilateral
patients (33%) with a p=0.0228. This
study shows that bilateral injections of
Botox are more efective in producing
optimal efect/side efect profles.
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Effect of Premedication with Midazolam on Recovery and
Discharge Times After Tonsillectomy and Adenoidectomy
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Midazolam premedication is widely
used before general anesthesia, but
remains controversial due to its
paradoxical side effects, including
over sedation, decreased blood pressure, and respiratory depression.
Patients with obstructive sleep apnea
(OSA) are at particularly high risk
for upper airway collapse as result of
worsened obstruction of the pharynx
after administration of sedatives,
anesthetics, and analgesics.1 While
professional guidelines, including
those from American Society of
Anesthesiologists, provide direction
regarding the perioperative management of OSA patients, focusing on
general risks of respiratory depression and airway collapse with sedatives and opioids, specifc guidance
with regards to midazolam on emergence and recovery time in pediatric
patients with moderate to severe
OSA undergoing tonsillectomy and
adenoidectomy (T&A) is limited. 2
We hypothesized that preoperative
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Midazolam

P value

No (n=387)

Yes (n=83)

Age, mean (SD)

3 7 (1 4)

3 4 (1 4)

0 14

Weight, mean (SD)

17 4 (7 8)

16 5 (6 3)

0 31

BMI, mean (SD)

16 9 (3 9)

16 8 (3 9)

0 88

Male

212 (54 8%)

51 (61 4%)

0 27

Female

175 (45 2%)

32 (38 6%)

African Am /Black

187 (48 4%)

29 (34 9%)

Caucasian

66 (17 1%)

18 (21 7%)

Hispanic/Latino

92 (23 8%)

24 (28 9%)

Other

41 (10 6%)

12 (14 5%)

Awake

68 (17 6%)

11 (13 3%)

Deep

319 (82 4%)

72 (86 7%)

1

56 (14 5%)

14 (16 9%)

2

295 (76 4%)

65 (78 3%)

3

35 (9 1%)

4 (4 8%)

Gender

Race
0 16

Awake or Deep
0 34

ASA score
0 41

*P values were obtained from t-test for continuous data, and Chi-square test for
categorical data

TABLE 1: Demographic characteristics by midazolam status
midazolam may increase emergence
and discharge times in pediatric
patients with OSA after T&A.
We conducted a retrospective
chart review of patients at Children’s
National Health System who underwent T&A between July 2014 and

December 2015. Patients who received
midazolam were compared to patients
who did not receive midazolam.
Demographic data included age,
gender, apnea-hypopnea score, body
Continued on p. 58
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Group

Mean emergence time
(95% CI), min*

No Midazolam

45 1 (39 9, 50 2)

Midazolam

50 3 (39 2, 61 4)

Difference
(95% CI),
min

P value

52
(-7 1, 17 4)

0 41

Mean discharge time
(95% CI), min*
115 8 (108 8, 122 9)
125 9 (110 7, 141 1)

Difference
(95% CI),
min

P value

10 1
(-6 7, 26 8)

0 24

TABLE 2: Emergence time, discharge time between Midazolam vs No Midazolam group
Continued from p. 57
mass index, diagnosis, American
Society of Anesthesiologists physical
status classifcation score, length of
surgery, and medications administered for anesthesia and recovery.
Data endpoints included emergence
and discharge times, perioperative
desaturations, postoperative apneic
episodes and delirium. Baseline
demographic characteristics were
compared using unpaired t-test for
continuous data and Chi-square test
for categorical data. Emergence and
discharge times were compared using
multiple linear regression, adjusting
for predefned potential confounding
factors.
There were no signifcant diferences in demographic characteristics
between the Midzolam (n=83) and No
Midazolam (n=387) groups. Likewise,
there were no signifcant diference
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in emergence or discharge times
between these two groups. After
adjusting for all potential confounders
(surgery duration, dexmedetomidine
and fentanyl doses adjusted to weight,
and awake or deep tracheal extubation status), emergence time was 5.2
minutes (95% CI: -7.1, 17.4) longer in
the Midazolam group (50.3 minutes,
95% CI: 39.2, 61.4) compared to the
No Midazolam group (45.1 minutes,
95% CI: 39.9, 50.2). This association
was not statistically significant (P=
0.41). After adjusting for potential
confounders (surgery duration, dexmedetomidine and fentanyl doses
dose adjusted to weight), discharge
time was 10.1 minutes (95% CI: -6.7,
26.8) longer in the Midazolam group
(125.9 minutes, 95% CI: 110.7, 141.1)
compared to the No Midazolam
group (115.8 minutes, 95% CI: 108.8,
122.9). This association was not statistically signifcant (P= 0.24).

Premedication with midazolam
was not associated with a prolonged
emergence or discharge time or with a
higher incidence of complications after
anesthesia for T&A in patients with
OSA. These data can help to further
characterize the best perioperative
management strategies in pediatric
patients with OSA undergoing T&A.
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Patent Ductus Arteriosus (PDA) is a
congenital heart defect that afects
about half of preterm infants born
before 32 weeks of gestation. When
pharmacotherapy with cycloox ygenase inhibitors like indomethacin
is unsuccessful or contraindicated,
patients must undergo surgical ligation of ductus arteriosus.1 However,
surgical ligation is signifcantly associated with neurodevelopmental
impairment (NDI) at two years of
age.2 Examples of NDI range from
cerebral palsy to compromised vision,
hearing, posture, language, cognition,
socialization, and coordination. In
addition, patients who underwent secondary surgical ligation demonstrated
higher NDI compared to those who
received indomethacin treatment
alone.1
Neurological fndings leading to
motor and cognitive delay in preterm
infants include intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), ventriculomegaly,
and hydrocephalus. Severity of the
frst three presentations can be determined via diferent grading systems
based on head ultrasounds (HUS)
and magnetic resonance imaging
(MRI). Importantly, the higher the
IVH or PVL grade, the higher the
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Post-operative neurological fndings
(IVH, PLV, ventriculomegaly, RI values)

Indomethacin
N = 54

Better

Mixed

Same

Worse

Missing

Yes

n = 17

8 (47 1%)

0 (0 0%)

7 (41 2%)

0 (0 0%)

2 (11 8%)

No

n = 37

15 (40 5%)

3 (8 1%)

9 (24 3%)

4 (10 8%)

6 (16 2%)

TABLE 1: Pre-operative indomethacin treatment and post-operative neurological
fndings
risk for ventriculomegaly as well
indomethacin use and post-operative
as nonoptimal neurodevelopment.
consultations in neurology, child
Furthermore, a progressive elevation
development, and physician mediin intracranial pressure (ICP) seen in
cine and rehabilitation ( PM&R)
hydrocephalus demonstrates a strong
were extracted from the charts.
correlation with increased resistive
Neurological imaging data from HUS,
index (RI) values of anterior cerebral
Doppler, and MRI were re-evaluated
artery (ACA), which is measured via
for IVH, PVL, cerebellar hemorDopper.3 In fact, infants with PDA
rhage, ventricular dilation, and RI
exhibited higher RI values than
values. Standard statistical methodthose without PDA. But among those
ology was applied.
who received surgical
ligation, there was no
[P]ost-operative consultations and screening
significant difference
between pre- and postmeasurements revealed that a majority
operative RI values.4
Ou r objectives
of patients who underwent PDA ligation
were to deter m i ne
the clinical complipresent with symptoms concerning for poor
ance with pre-operative indomethacin
neurodevelopmental outcomes.
treatment as well as
post-operative neurodevelopmental screening and conFifty-four patients were identifed
sultations. Given that the risk for
(27M/27F; mean [SD] gestational age
NDI is higher with surgical ligation,
25.2 [2.74] weeks). Of these patients,
an understanding of the current
all seven infants (13.0%), who demonscreening methodology is needed for
strated worse or mixed postoperative
improvement of care.
fndings in terms of RI values and venA three-year retrospective chart
triculomegaly, had not received indomethacin prior to surgical ligation
review of premature infants who
(primary ligation) (Table 1). In two of
received PDA ligation at Children’s
National Hospital was performed.
Information regarding pre-operative
Continued on p. 60
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Continued from p. 59
those patients, indomethacin was contraindicated because of evolving IVH
and/or coagulopathy. Additionally, 32
infants (59.3%) received postoperative
consultations in child development,
neurology and/or PM&R; the other
22 infants did not have them on fle.
Out of the 32 cases, 29 infants (90.6%)
exhibited developmental delay and/
or neurological abnormalities on
their frst visits. Only three patients
(9.4%) developed normally across all
domains and lacked any signifcant
neurological abnormalities after PDA
ligation (Table 2).
In conclusion, the retrospective
chart review demonstrated a potential
correlation between the lack of preoperative indomethacin treatment
and worse or mixed neurological fndings after PDA ligation. Additionally,
post-operative consultations and
screening measurements revealed that
a majority of patients who underwent
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First postoperative consultations
(child development, neurology, PM&R)
n = 32
Developmental delay ± neurological abnormalities
Normal development without
neurological abnormalities

29 (90 6%)
3 (9 4%)

TABLE 2: Neurodevelopmental fndings based on frst post-operative consultations
PDA ligation present with symptoms
concerning for poor neurodevelopmental outcomes. Although preterm
infants selected for surgical ligation
may have a higher pre-ligation risk
for NDI,1 the reported prevalence of
neurodevelopmental abnormalities
may also be underestimated due to the
lack of post-operative screening and
follow-ups. Thus, the study highlights
the need for a better neurodevelopmental screening protocol for preterm
infants receiving PDA ligation.
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Glioblastoma multiforme (GBM)
is the most common and aggressive
primar y centra l ner vous system
(CNS) neoplasm in adults. Diagnosis
with GBM confers a dismal prognosis
due to four main characteristics of
the malignancy: (1) extensive proliferative, angiogenic, migrative, and
invasive capabilities that result in an
incredibly tolerable tissue, (2) microinvasion limiting the ability to perform gross total surgical resection, (3)
a heterogeneous cell population that
responds diferentially to treatment
within the same mass, and (4) downregulation of the immune system
in the tumor microenvironment,
enabling immune evasion. The current standard of care for the treatment
of GBM includes a combination of
radiation therapy, surgical resection,
and medical management (temozolomide/TMZ at initial presentation and
bevacizumab at recurrence). With a
median post-diagnosis survival time
of 15–16 months in patients receiving
multifaceted treatment (chemotherapy, radiation, and surgery), any
innovation with the potential to
either independently target or synergistically improve other, currently
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FIGURE 1: Cold Atmospheric Plasma and The Activation State
(a) Plasma is the fourth state of matter (b) Cold atmospheric plasma is generated by
passing a carrying gas through high voltage to generate an array of emitted ionized
particles (c) Short treatment with cold atmospheric plasma sensitizes cancer cells to
chemotherapy to generate an activation state
available treatment modalities for
GBM is of great interest to neurooncology providers and patients.
Cold atmospheric plasma (CAP)
is a high energ y ionized state of
matter (Figure 1A) that can be applied
directly as a microjet or indirectly as
an injection to tissue (figure 1B) as
a means of immediately and selectively sensitizing cancer cells to

chemotherapeutics.1,5 The maximum
threshold of sensitization, termed
the “activation state”, can be reached
within 20 seconds of CAP treatment (Figure 1C). De-sensitization,
however, takes fve hours after CAP
treatment.2,3 By applying an electrical
feld to a carrying gas (usually helium
Continued on p. 62
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Continued from p. 61

A
or argon), CAP is thought to exert its
anti-cancer efects by generating reactive oxygen and nitrogen species that
selectively damage neoplastic cells
due to their pre-existing oxidative
stress from high metabolic activity.4
In this study we demonstrate the
existence of a CAP-induced activation state among human glioblastoma
(U87) cells which confers increased
sensitivity to TMZ and reactive species from H2O2 as quantifed via cell
viability.

Results
Direct treatment with CA P for
60 seconds sensitized U87 cells to
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Methods
The CAP device was designed and
assembled in the Keidar lab at the
George Washington Universit y.
This device used helium as the carrying gas at a fow rate of 8L / min.
Electrodes were connected to a high
voltage resonant transformer (8 kV
peak to peak, 12.5 Hz). Optical emission spectroscopy was used to characterize the plasma. U87 cells were
cultured in DMEM supplemented
by 1% penicillin/streptomycin and
10% FBS. CAP was delivered to U87
cells in a 96-well plate for 1 minute in
combination with 10 µM H2O2, 15 µM
H2O2, 10 µM TMZ, or 50 µM TMZ
in a total volume of 50 µL of media
during treatment. Cell viability was
measured by a standard MTT assay
and the Cell Titer Glo 2.0 luminescent
assay after three days of incubation.

B

"

FIGURE 2: Cell Viability After Treatment in the Activation State
(a) Schematic of the experiment Cell viability after treatment with (b) TMZ and (c) TMZ
+ CAP
treatment with TMZ at concentrations of 10 µM and 50 µM (Figure 2).

of Cold Atmospheric Plasma for in Vitro
Treatment of Cancer Cells. ACS Applied
Materials & Interfaces. 10(11), 9269–9279.
doi: 10.1021/acsami.7b18653

Conclusions
Treatment of U87 cells with CAP
produced an activation state that
sensitized cells to treatment by H2O2
and TMZ. This drastic increase in
cytotoxicity from a widely used drug
provides encouraging evidence to
support further research and the possible clinical application of CAP as an
adjunct to existing therapy for GBM.
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Manufactured, Synthetic Fascia for Training
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Characteristic

Similar to Human
Fascia

Stronger
pull-through
force/ larger
needle hole

Weaker
pull-through
force/ smaller
needle hole

Moas, MD,1 Peter
Liacouras, PhD,2
Stephen Goldman,
PhD,1 Spencer
VanDecar, BS,3
Brenton Franklin, MD,3 Matthew Ritter, MD,3
William Sweeney, MD,3 and Jason Souza, MD1

Needle hole
enlargement

9

-

1

Suture-pull through

4

6

-

1Walter Reed National Military Medical Center
2National Military Medical Center
3Uniformed Services University of the Health
Sciences, Bethesda, MD

Response to cutting

4

5

1

Tactile Feel (upon
palpation)

-

7

3

Drag of needle

3

6

1

Grasping behavior
(with Kocher clamps
and forceps)

3

5

2

Few models to train fascial closure
are currently available. Cadaveric or
porcine fascia based training is not
ideal due to signifcant inter-specimen
variability, low supply, cost, and ethical concerns. We aimed to create an
inexpensive and easily manufactured
synthetic fascia suitable for simulation-based fascial closure training.

Methods
Synthetic fascia constructs were
manufactured using combinations of
various silicones and mesh materials.
Constructs were biomechanically
evaluated via tensile suture pullthrough testing. Iterative testing
provided direction for each fascia
construct with the goal of achieving
pull-through forces within 10N of
the average strength of porcine fascia.
Each construct was qualitatively
assessed by the surgeon authors
to optimize the tactile feel, suture
drag, and thickness compared with
human fascia. The construct with
the best biomechanical profile was
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Similar to Human
Fascia

Somewhat
Not similar to
similar to
Human Fascia
Human Fascia

TABLE: Qualitative survey evaluating synthetic fascia characteristics (n= number of
surgeons)

qualitatively evaluated by ten surgeons experienced in fascial closure.
Respondents were instr ucted to
create four 3cm incisions and grasp
the fascia with a Kocher clamp and
toothed forceps. Incisions were then
closed with 2-0 polypropylene and
1 polydioxanone sutures, using both
1cm bites/1cm advancement and 5mm
bites/5 mm advancement techniques.

Results
The optimized synthetic fascia was
created using a combination of silicone and powermesh with material
cost for one 24x24cm sheet of $4.09
and a one-time cost for mold creation
of $50. Manufacturing time for each
fascial sheet was 20 minutes with a

16 hour curing time. 9/10 surgeons
rated the construct as an acceptable
teaching tool for abdominal fascial
closures with only one respondent
stating the construct felt “unnatural”.
The table below shows the breakdown
of responses for each performance
characteristic.

Conclusions
We describe a synthetic fascia construct that is inexpensive, easily manufactured, mimics the biomechanical
profle of porcine fascia, and performs
similar to human fascia as assessed
by a group of experienced surgeons.
Its use in simulation-based training
should be encouraged and outcomes
measured.
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Distal radius fractures are the most
common long bone fracture in the
pediatric population and frequently
requ i re ca sti n g for treatment.
Traditional casts are heavy, bulky,
susceptible to water damage, and
frequently lead to cutaneous and
n e u r o v a s c u l a r com pl i c a t ion s .
The incidence of cast-related skin
complications is approximated to
be 13.6 per 1,000 patients.1 Current
3D laser sca nning a nd printing
tech nolog y en ables phy sicia n s
to take 3D images of a limb and
create a customized, biocompatible
cast that is lightweight, thin, and
waterproof. Chen et al. have shown
that 3D-printed casts of distal radius
fractures have comparable clinical
effectiveness compared to plaster
casts. 2 Here we have developed a
c ustom ized a nd biocompatible
3D-printed cast that can be used for
treatment of minimally displaced
distal radius fractures in pediatric
patients.

Methods:
The forearm of a sample patient was
scanned using the handheld Artec Eva
Lite 3D scanner. The 3D image was
uploaded into Geomagic and used to
create a two-piece hollow-shell cast
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FIGURE: A, the dorsal view of the 3D-printed cast B, the lateral view of the
3D-printed cast
with computer assisted design (CAD).
cast was ofset from the skin of our
The fles were then sent to Xometry®,
sample patient by 1.75mm to allow
a 3D-printing company, to be printed
for expected post-traumatic tissue
u si n g M E D610 bio compat ible
edema and prevent compartment
m ater i a l (a d u r a ble
polymer-based material
Current 3D laser scanning and printing
approved by the FDA for
prolonged skin contact).
technology enables physicians to take 3D
The cast was designed
in two pieces to allow
images of a limb and create a customized,
for easy placement on
the forearm. Zip ties
biocompatible cast that is lightweight, thin,
were used to enclose the
cast around the forearm
and waterproof.
circumferentially. Holes
were i ntentiona l ly
syndrome. Our sample patient wore
printed in the design to allow for
this cast for two days (removed for
facile evaporation of water and sweat.
showering and sleeping) and did not
Results:
have any cutaneous or neurovascular
A 3 D - pr i nte d c a s t ( Fi g u r e A
complications.
and B) was printed on MED610
Conclusions
biocompatible material according
to our specifcations obtained from
I n t h i s work , we s ucces sf u l l y
the Artec® Eva Lite 3D scanner. The
developed a customized,
thickness of the cast was 5 mm. The
biocompatible 3D-printed forearm
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cast with the potentia l to treat
minimally displaced radius fractures
in orthopedic pediatric patients. Our
future research will assess the clinical
efectiveness and rate of cutaneous
and neurovascular complications
with the use of the cast compared to
traditional casts in children aged 5 to
12 with minimally displaced radius
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fractures. These studies will provide
a foundation for clinical trials to test
the efectiveness of our 3D-printed
casts in treating injuries requiring
prolonged immobilization.
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